var docs;if (!docs) docs =[]; docs["94"]={"9400":"<p><b>Title</b> NiMODipine / CYP3A4 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nimodipine effects in patients receiving weak CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Weak) Interacting Members</b> ALPRAZolam, Amiodarone, AmLODIPine, AtorvaSTATin, Bicalutamide, Bitter Orange, Cilostazol, Cimetidine, Ciprofloxacin (Systemic), Clotrimazole (Oral), CycloSPORINE (Systemic), Danazol, Dasatinib, Delavirdine, Everolimus, FluvoxaMINE, Fosaprepitant, Glecaprevir and Pibrentasvir, Goldenseal, Grazoprevir, Iloperidone, Isoniazid, Ivacaftor, Lapatinib, Lomitapide, Lurasidone, NiCARdipine, Palbociclib, PAZOPanib, Peppermint, Piperaquine, Propiverine, Propofol, QuiNIDine, Quinupristin, Ranolazine, Resveratrol, Roxithromycin, Ticagrelor, Tofisopam</p>\n</div> \n<p><b>Discussion</b> Nimodipine US prescribing information states that patients using nimodipine in combination with weak CYP3A4 inhibitors should be monitored for increased nimodipine effects.<sup>1</sup> The suspected mechanism of this interaction is inhibition of CYP3A4-mediated nimodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9401":"<p><b>Title</b> Tacrolimus (Systemic) / Schisandra</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Schisandra may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor tacrolimus therapy closely when used together with Schisandra-containing products, including close monitoring of tacrolimus whole blood concentrations. Particular attention will likely be necessary when starting or stopping a Schisandra-containing product. Tacrolimus dose reductions may be necessary.</p> \n<p><b>Discussion</b> Several studies have reported increased tacrolimus concentrations and reduced dose requirements in studies of both post-transplant patients and healthy volunteers (n=12 to 64) with concurrent use of schisandra.<sup>1,2,3,4</sup> Tacrolimus AUC has reportedly increased between 2.6- and 3.1-fold,<sup>1,2</sup> with dose-corrected concentrations increasing approximately 2-fold<sup>3</sup> and average concentrations increasing 3.6- to 4.4-fold.<sup>1</sup> The average dose-requirement decreased between 25% and 35%.<sup>3,4</sup><br><br>This interaction appears to be the result of schisandra inhibition of the CYP3A-mediated metabolism of tacrolimus and/or inhibition of tacrolimus transport via p-glycoprotein.<sup>5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jiang W, Wang X, Xu X, Kong L. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. <i>Int J Clin Pharmacol Ther</i>. 2010;48(3):224-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20197017\">[PubMed 20197017]</a></p>\n<p>2. Xin HW, Wu XC, Li Q, et al. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2007;64(4):469-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17506780\">[PubMed 17506780]</a></p>\n<p>3. Xin HW, Li Q, Wu XC, et al. Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients. <i>Eur J Clin Pharmacol</i>. 2011;67(12):1309-1311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21656210\">[PubMed 21656210]</a></p>\n<p>4. Sun Z, Ren M, Wu Q, Du X. Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics. <i>Int Urol Nephrol</i>. 2014;46(10):1977-1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25145781\">[PubMed 25145781]</a></p>\n<p>5. Xin HW, Wu XC, Li Q, Yu AR, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2009;67(5):541-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19552749\">[PubMed 19552749]</a></p>\n<p>6. Qin XL, Chen X, Wang Y, et al. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. <i>Drug Metab Dispos</i>. 2014;42(1):193-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24195812\">[PubMed 24195812]</a></p>\n<p>7. Qin XL, Bi HC, Wang XD, et al. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). <i>Int J Pharm</i>. 2010;389(1-2):114-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20097278\">[PubMed 20097278]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9402":"<p><b>Title</b> Calcitriol (Systemic) / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum calcium concentrations and other laboratory measures of calcitriol effectiveness when used in conjunction with systemic corticosteroids, particularly when starting, stopping, or changing corticosteroid doses.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Systemic corticosteroids have been shown to impair intestinal calcium absorption, an effect that opposes that of calcitriol, which works to enhance calcium absorption. Several studies have found that therapeutic doses of corticosteroids impair intestinal calcium absorption.<sup>1,2,3</sup> This corticosteroid effect has been shown to be dose-dependent, and the effect is reportedly less significant with alternate-day (vs. daily) dosing.<sup>1</sup><br><br>It is unclear whether the effect of corticosteroids on calcium absorption is related to alterations in vitamin D metabolism. Studies have reported that corticosteroids alter vitamin D metabolism (e.g., decreased activation of 25-hydroxy-vitamin D, increased metabolism of calcitriol, etc.),<sup>1,4</sup> but others have found evidence that corticosteroid-related changes in calcium absorption may be independent of changes in vitamin D metabolism.<sup>5</sup> Regardless of the specific mechanism involved, several studies have confirmed that active vitamin D analogs such as calcitriol remain effective at promoting calcium absorption in patients being treated with corticosteroids.<sup>1,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. <i>J Clin Invest</i>. 1977;60(1):253-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=874087\">[PubMed 874087]</a></p>\n<p>2. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of cortisone treatment on the active transport of calcium by the small intestine. <i>J Clin Invest</i>. 1971;50(6):1309-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4325312\">[PubMed 4325312]</a></p>\n<p>3. Lukert BP, Stanbury SW, Mawer EB. Vitamin D and intestinal transport of calcium: effects of prednisolone. <i>Endocrinology</i>. 1973;93(3):718-722. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4352809\">[PubMed 4352809]</a></p>\n<p>4. Carre M, Ayigbede O, Miravet L, Rasmussen H. The effect of Prednisolone upon the metabolism and action of 25-hydroxy-and 1,25-dihydroxyvitamin D3. <i>Proc Natl Acad Sci U S A</i>. 1974;71(8):2996-3000. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4528777\">[PubMed 4528777]</a></p>\n<p>5. Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. <i>J Clin Endocrinol Metab</i>. 1981;52(1):111-115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6969728\">[PubMed 6969728]</a></p>\n<p>6. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. <i>Osteoporos Int</i>. 2004;15(8):589-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15138667\">[PubMed 15138667]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9403":"<p><b>Title</b> Magnesium Salts / Calcitriol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcitriol (Systemic) may increase the serum concentration of Magnesium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> The calcitriol product labeling warns against the combined use of magnesium products and calcitriol, due to the risk for developing hypermagnesemia,<sup>1</sup> and this is based mostly on the known actions of calcitriol on magnesium absorption and elimination. Studies in humans<sup>2</sup> and rats<sup>3</sup> have shown that calcitriol stimulates magnesium absorption in the intestine<sup>2</sup> and colon.<sup>3</sup> Studies in mouse distal convoluted tubule cells have also shown that calcitriol stimulates magnesium uptake in these cells,<sup>4</sup> which are known to play an important role in magnesium reabsorption.<br><br>The population likely to be at the greatest risk for developing hypermagnesemia due to this interaction are those with chronic renal failure and/or those on chronic dialysis, given alterations in magnesium, calcium, and phosphorous handling common in such patients. Though magnesium salts are generally considered to have no advantage over other phosphate binders in these patients,<sup>5</sup> reports of successful combined use of magnesium products and calcitriol in both chronic renal failure<sup>6</sup> and chronic hemodialysis patients<sup>7</sup> do exist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012.</p>\n<p>2. Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. <i>Boll Soc Ital Biol Sper</i>. 1981;57(7):791-797. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6895034\">[PubMed 6895034]</a></p>\n<p>3. Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. <i>Digestion</i>. 1987;37(1):35-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3609503\">[PubMed 3609503]</a></p>\n<p>4. Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. <i>Am J Physiol Renal Physiol</i>. 2001;280(5):F868-F878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11292630\">[PubMed 11292630]</a></p>\n<p>5. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. <i>Drug Saf</i>. 2003;26(15):1093-1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14640773\">[PubMed 14640773]</a></p>\n<p>6. Lindeman RD. Chronic renal failure and magnesium metabolism. <i>Magnesium</i>. 1986;5(5-6):293-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3807422\">[PubMed 3807422]</a></p>\n<p>7. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. <i>Kidney Int</i>. 1996;49(1):163-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8770963\">[PubMed 8770963]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9404":"<p><b>Title</b> Calcitriol (Systemic) / Sevelamer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction likely applies only to orally administered calcitriol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sevelamer may decrease the serum concentration of Calcitriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for evidence of reduced clinical response to calcitriol when administered with sevelamer.</p> \n<p><b>Discussion</b> The average calcitriol AUC was 57% lower when calcitriol (1 mcg at lunch) was administered with sevelamer (7200 mg/day, given as 2400 mg with breakfast, 2400 mg with lunch, and 2400 mg with dinner) in a study of 41 healthy volunteers.<sup>1</sup> Similarly, the average calcitriol maximum plasma concentration (Cmax) was 24% lower with concurrent sevelamer. Clinical trials comparing sevelamer to other phosphate binders, however, have not reported any evidence to suggest that this potential interaction has a significant effect on the clinical effectiveness of this combination.<sup>2,3</sup> Despite this uncertain significance, it seems prudent to monitor clinical response to calcitriol more closely when used with sevelamer until the exact significance of this reported interaction is better understood.<br><br>The mechanism for this interaction is not certain, but given the nature of sevelamer as binding agent and data suggesting potential absorption-related interactions with vitamin D and other fat-soluble vitamins,<sup>4</sup> sevelamer-related interference with calcitriol absorption is a possible mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. <i>Nephrol Dial Transplant</i>. 2011;26(5):1615-1621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20921291\">[PubMed 20921291]</a></p>\n<p>2. Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. <i>J Am Soc Nephrol</i>. 2005;16(8):2501-2508. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15944337\">[PubMed 15944337]</a></p>\n<p>3. Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. <i>Kidney Int</i>. 2011;79(1):112-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20861820\">[PubMed 20861820]</a></p>\n<p>4. Renvela (sevelamer carbonate) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9405":"<p><b>Title</b> Bismuth Subcitrate / Bismuth-Containing Compounds</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of bismuth subcitrate (tripotassium bismith dicitrate) together with other bismuth-containing products is not advisable. Avoid such combinations when possible.</p>\n<div>\n <p><b>Bismuth-Containing Compounds Interacting Members</b> Bismuth Subcitrate, Bismuth Subgallate, Bismuth Subsalicylate</p>\n</div> \n<p><b>Discussion</b> The bismuth subcitrate (tripotassium bismith dicitrate) summary of product characteristics cautions that concurrent use of bismuth subcitrate together with other bismuth-containing products is not advisable due to a possible increase in the risk for neurotoxicity.<sup>1</sup> Bismuth is absorbed following oral administration, and bismuth has been associated with neurotoxicity.<sup>1,2,3</sup> Concurrent use of multiple bismuth-containing products would be expected to result in higher systemic bismuth concentrations and to a greater risk for toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</p>\n<p>2. Nwokolo CU, Gavey CJ, Smith JT, Pounder RE. The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. <i>Aliment Pharmacol Ther</i>. 1989;3(1):29-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2491456\">[PubMed 2491456]</a></p>\n<p>3. Masannat Y, Nazer E. Pepto bismuth associated neurotoxicity: A rare side effect of a commonly used medication. <i>W V Med J</i>. 2013;109(3):32-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23798279\">[PubMed 23798279]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9406":"<p><b>Title</b> Tetracyclines / Bismuth Subcitrate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bismuth Subcitrate may decrease the serum concentration of Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate (tripotassium bismith dicitrate) administration. Note that this interaction is not thought to be of significance for at least some regimens intended to treat <i>H. pylori</i> infections, such as the co-formulated bismith subcitrate, metronidazole, and tetracycline (Pylera brand) product.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Tetracycline absorption was reduced by an average of 34% with concurrent administration of liquid bismuth subsalicylate in one study,<sup>1</sup> and the tetracycline AUC was reduced by an average of 27% with concurrent administration of liquid bismuth subsalicylate in another study of healthy volunteers.<sup>2</sup> The labeling for multiple bismuth subcitrate products cautions that concurrent use with tetracyclines may reduce the absorption and/or efficacy of orally-administered tetracyclines.<sup>3,4</sup><br><br>The degree to which this interaction is due to bismuth is uncertain, as the magnesium aluminum silicate present in the oral liquid preparations of bismuth subsalicylate is suspected to participate to at least some extent. An oral bismuth subsalicylate product without magnesium aluminum silicate was associated with an average 13% reduction in tetracycline AUC with coadministration,<sup>2</sup> suggesting that bismuth itself does participate in the interation, though to a lesser extent than oral preparations containing magnesium aluminum silicate.<br><br>A bismuth subcitrate product recommends avoiding administration of oral tetracyclines within 30 minutes of bismuth subcitrate (tripotassium bismith dicitrate) administration,<sup>3</sup> but the Pylera brand of a co-formulated bismith subcitrate, metronidazole, and tetracycline product acknowledges the interaction but states that it is not expected to alter the local anti- <i>H. pylori</i> actions of tetracycline.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Albert KS, Welch RD, DeSante KA, DiSanto AR. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. <i>J Pharm Sci</i>. 1979;68(5):586-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=435335\">[PubMed 435335]</a></p>\n<p>2. Healy DP, Dansereau RJ, Dunn AB, Clendening CE, Mounts AW, Deepe GS Jr. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. <i>Ann Pharmacother</i>. 1997;31(12):1460-1464. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9416381\">[PubMed 9416381]</a></p>\n<p>3. De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</p>\n<p>4. Pylera (bismuth subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9407":"<p><b>Title</b> Bismuth Subcitrate / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may diminish the therapeutic effect of Bismuth Subcitrate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismith dicitrate) administration.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The bismuth subcitrate summary of product characteristics recommends avoiding use of antacids within 30 minutes of bismuth subcitrate administration due to concerns that antacids may alter bismuth subcitrate effectiveness.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9408":"<p><b>Title</b> Fimasartan / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Fimasartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased fimasartan effects/toxicities if combined with cyclosporine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, the OATP/SLCO1B1 inhibitor rifampin (600 mg once daily for 9 days) increased the fimasartan (240 mg single oral dose) AUC and maximum serum concentration 4.6- and 10.3-fold, respectively.<sup>1,2</sup><br><br>Fimasartan product labeling recommends avoiding the combination of fimasartan and rifampin due to the increase in fimasartan concentrations and risk for adverse events.<sup>2</sup> Since cyclosporine is also a OATP/SLCO1B1 inhibitor, fimasartan prescribing information warns that concomitant use may also increase fimasartan concentrations and patients should be monitored for increased fimasartan effects and toxicities.<sup>2</sup><br><br>The likely mechanism of this interaction is rifampin, and likely cyclosporine, inhibition of OATP/SLCO1B1, a transporter responsible for fimasartan hepatic uptake. Without adequate hepatic uptake, metabolism and biliary excretion of fimasartan is reduced, resulting in increased systemic exposure.<sup>1</sup> Cyclosporine inhibition of CYP3A4 may also play a role.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kim JW, Yi S, Kim TE, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. <i>J Clin Pharmacol</i>. 2013;53(1):75-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23400746\">[PubMed 23400746]</a></p>\n<p>2. Fimasartan [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201005500. Accessed December 14, 2014. </p>\n<p>3. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9409":"<p><b>Title</b> Fimasartan / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Fimasartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased fimasartan effects/toxicities if combined with ketoconazole.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, ketoconazole (400 mg once daily for 4 days), increased the fimasartan (240 mg single oral dose) AUC and maximum serum concentration 2.0- and 2.5-fold, respectively.<sup>1,2</sup><br><br>Fimasartan product labeling states that if fimasartan and ketoconazole are used concomitantly patients should be monitored for increased fimasartan effects and toxicities.<sup>2</sup><br><br>The likely mechanism of this interaction is ketoconazole inhibition of OATP/SLCO1B1, a transporter responsible for fimasartan hepatic uptake. Without adequate hepatic uptake, metabolism and biliary excretion of fimasartan is reduced, resulting in increased systemic exposure.<sup>1</sup> Ketoconazole inhibition of CYP3A4 may also play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kim JW, Yi S, Kim TE, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. <i>J Clin Pharmacol</i>. 2013;53(1):75-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23400746\">[PubMed 23400746]</a></p>\n<p>2. Fimasartan [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201005500. Accessed December 14, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9410":"<p><b>Title</b> Fimasartan / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may increase the serum concentration of Fimasartan. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of fimasartan and rifampin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, rifampin (600 mg once daily for 9 days) increased the fimasartan (240 mg single oral dose) AUC and maximum serum concentration 4.6- and 10.3-fold, respectively.<sup>1,2</sup><br><br>Fimasartan product labeling recommends avoiding the combination of fimasartan and rifampin due to the increase in fimasartan concentrations and risk for adverse events.<sup>2</sup><br><br>The likely mechanism of this interaction is rifampin inhibition of OATP/SLCO1B1, a transporter responsible for fimasartan hepatic uptake. Without adequate hepatic uptake, metabolism and biliary excretion of fimasartan is reduced, resulting in increased systemic exposure.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kim JW, Yi S, Kim TE, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. <i>J Clin Pharmacol</i>. 2013;53(1):75-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23400746\">[PubMed 23400746]</a></p>\n<p>2. Fimasartan [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201005500. Accessed December 14, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9411":"<p><b>Title</b> AtorvaSTATin / Fimasartan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fimasartan may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action needed.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, fimasartan (240 mg single oral dose) increased the atorvastatin acid (atorvastatin 80 mg single oral dose) AUC and maximum serum concentration (Cmax) 1.2- and 1.9-fold, respectively, although the change in AUC did not reach statistical significance.<sup>1</sup> The AUC and Cmax of the 2-hydroxy atorvastatin acid metabolite increased 1.4- and 2.5-fold, respectively. The atorvastatin lactone and 2-hydroxy atorvastatin lactone Cmax increased 1.3- and 1.5-fold, respectively, while the AUCs were unchanged.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but fimasartan inhibition of OATP/SLCO1B1, a transporter responsible for the hepatic uptake of atorvastatin, may play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim TE, Kim SE, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. <i>J Cardiovasc Pharmacol</i>. 2011;58(5):492-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21765368\">[PubMed 21765368]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9412":"<p><b>Title</b> Bismuth-Containing Compounds / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Omeprazole may increase the serum concentration of Bismuth-Containing Compounds. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Bismuth-Containing Compounds Interacting Members</b> Bismuth Subcitrate, Bismuth Subgallate, Bismuth Subsalicylate</p>\n</div> \n<p><b>Discussion</b> Bismuth AUC and maximum serum concentration (Cmax) were an average of 2.9- and 3.2-fold higher, respectively, with concurrent omeprazole in a study where subjects received co-formulated bismuth subcitrate, metronidazole, and tetracycline with or without concurrent omeprazole (20 mg twice/day).<sup>1,2</sup><br><br>This is considered to be of low clinical significance as the bismuth Cmax remained below the threshold of concern.<sup>1,2</sup> The mechanism for this apparent interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. <i>J Clin Pharmacol</i>. 2004;44(6):640-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15145972\">[PubMed 15145972]</a></p>\n<p>2. Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9413":"<p><b>Title</b> Digoxin / Fimasartan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fimasartan may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. The observed changes in digoxin pharmacokinetics are small and unlikely to be clinically significant.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy volunteers, fimasartan (240 mg once daily for 6 days) increased the digoxin (0.5 mg single oral dose, then 0.25 mg 6 hours later, then 0.25 mg daily for 6 days) maximum serum concentration 1.3-fold but did not affect the digoxin AUC.<sup>1</sup> Digoxin minimum (trough) serum concentrations were also unchanged.<br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yi S, Kim JW, Kim TE, et al. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. <i>Int J Clin Pharmacol Ther</i>. 2011;49(5):321-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21543035\">[PubMed 21543035]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9414":"<p><b>Title</b> Mecamylamine / Urinary Acidifying Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects or reduced efficacy of mecamylamine if used with urinary acidifying agents.</p>\n<div>\n <p><b>Urinary Acidifying Agents Interacting Members</b> Ammonium Chloride, Methenamine, Piperazine, Potassium Phosphate, Sodium Acid Phosphate</p>\n</div> \n<p><b>Discussion</b> In one uncontrolled study, patients with essential hypertension and normal renal function received mecamylamine (various doses) alone and after urinary alkalinization with sodium bicarbonate (2 g every 4 hours) and urinary acidification with ammonium chloride (2 g every 4 hours).<sup>1</sup> Within 24 hours, the urinary excretion of mecamylamine was reduced to less than 10% with urinary alkalinization, but was increased to over 50% with urinary acidification.<sup>1</sup><br><br>Prescribing information for mecamylamine states that the rate of mecamylamine elimination is influenced markedly by urinary pH and that acidification of the urine increases renal excretion of mecamylamine.<sup>2</sup><br><br>The proposed mechanism of this interaction is that mecamylamine exists in a more ionized and less reabsorbable form in an acidic environment. Thus, less drug is reabsorbed, leading to increased urinary excretion and decreased drug exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Allanby KD, Trounce JR. Excretion of mecamylamine after intravenous and oral administration. <i>Br Med J</i>. 1957;2(5055):1219-1221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13472094\">[PubMed 13472094]</a></p>\n<p>2. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9415":"<p><b>Title</b> Mecamylamine / Alkalinizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alkalinizing Agents may increase the serum concentration of Mecamylamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects and toxicities of mecamylamine if used with agents able to alkalinize the urine.</p>\n<div>\n <p><b>Alkalinizing Agents Interacting Members</b> Potassium Citrate, Sodium Bicarbonate, Sodium Citrate, Sodium Lactate, Tromethamine</p>\n</div> \n<p><b>Discussion</b> In one uncontrolled study, patients with essential hypertension and normal renal function received mecamylamine (various doses) alone and after urinary alkalinization with sodium bicarbonate (2 g every 4 hours) and urinary acidification with ammonium chloride (2 g every 4 hours).<sup>1</sup> Within 24 hours, the urinary excretion of mecamylamine was reduced to less than 10% with urinary alkalinization, but was increased to over 50% with urinary acidification.<sup>1</sup><br><br>Prescribing information for mecamylamine states that the rate of mecamylamine elimination is influenced markedly by urinary pH and that alkalinization of the urine reduces renal excretion of mecamylamine.<sup>2</sup><br><br>The proposed mechanism of this interaction is that mecamylamine exists in a more nonionized and reabsorbable form in an alkaline environment. Thus, more drug is reabsorbed, leading to reduced urinary excretion and increased drug exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Allanby KD, Trounce JR. Excretion of mecamylamine after intravenous and oral administration. <i>Br Med J</i>. 1957;2(5055):1219-1221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13472094\">[PubMed 13472094]</a></p>\n<p>2. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9416":"<p><b>Title</b> Mecamylamine / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and aminoglycosides.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics (ie, aminoglycosides) and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1,2,3,4,5</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Warner WA, Sanders E. Neuromuscular blockade associated with gentamicin therapy. <i>JAMA</i>. 1971;215(7):1153-1154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4250687\">[PubMed 4250687]</a></p>\n<p>3. Levanen J, Nordman R. Complete respiratory paralysis caused by a large dose of streptomycin and its treatment with calcium chloride. <i>Ann Clin Res</i>. 1975;7(1):47-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1155911\">[PubMed 1155911]</a></p>\n<p>4. Holtzman JL. Letter: Gentamicin and neuromuscular blockade. <i>Ann Intern Med</i>. 1976;84(1):55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1244797\">[PubMed 1244797]</a></p>\n<p>5. Boliston TA, Ashman R. Tobramycin and neuromuscular blockade. <i>Anaesthesia</i>. 1978;33(6):552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=686321\">[PubMed 686321]</a></p>\n<p>6. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9417":"<p><b>Title</b> Mecamylamine / Lincosamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and lincosamide antibiotics.</p>\n<div>\n <p><b>Lincosamide Antibiotics Interacting Members</b> Clindamycin (Systemic), Lincomycin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics (ie, lincosamides) and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1,2,3,4</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides (an antibiotic class associated with neuromuscular blockade) produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Lincocin (lincomycin) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; June 2007.</p>\n<p>4. Cleocin phosphate (clindamycin phosphate) [prescribing information]. New York, NY: Pfizer Inc; April 2014.</p>\n<p>3. al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. <i>Can J Anaesth</i>. 1995;42(7):614-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7553999\">[PubMed 7553999]</a></p>\n<p>4. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9418":"<p><b>Title</b> Mecamylamine / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and tetracycline antibiotics.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1</sup> Tetracycline antibiotics, while not typically associated with neuromuscular blockade, have been shown to exert some neuromuscular blocking effects in animal models.<sup>2,3,4</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides (an antibiotic class associated with neuromuscular blockade) produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Singh YN, Marshall IG, Harvey AL. Pre- and postjunctional blocking effects of aminoglycoside, polymyxin, tetracycline and lincosamide antibiotics. <i>Br J Anaesth</i>. 1982;54(12):1295-1306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6293521\">[PubMed 6293521]</a></p>\n<p>3. Hashimoto Y, Shima T, Matsukawa S, Iwatsuki K. Neuromuscular blocking property of minocycline in the rabbit. <i>Tohoku J Exp Med</i>. 1979;129(2):203-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=227141\">[PubMed 227141]</a></p>\n<p>4. Yamada S, Kuno Y, Iwanaga H. Effects of several antibiotics on the neuromuscular junction: Part II. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1986;24(4):171-179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3486835\">[PubMed 3486835]</a></p>\n<p>5. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9419":"<p><b>Title</b> Mecamylamine / Capreomycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Capreomycin may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and capreomycin.</p> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics (ie, capreomycin) and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1,2</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides (an antibiotic class associated with neuromuscular blockade) produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Capastat (capreomycin) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, January 2008.</p>\n<p>3. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9420":"<p><b>Title</b> Mecamylamine / Colistimethate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Colistimethate may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and colistimethate.</p> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics (ie, colistimethate) and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1,2,3</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides (an antibiotic class associated with neuromuscular blockade) produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Pittinger CB, Eryasa Y, Adamson R. Antibiotic-induced paralysis. <i>Anesth Analg</i>. 1970;49(3):487-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102601\">[PubMed 4102601]</a></p>\n<p>3. Giala MM, Paradelis AG. Two cases of prolonged respiratory depression due to interaction of pancuronium with colistin and streptomycin. <i>J Antimicrob Chemother</i>. 1979;5(2):234-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=429254\">[PubMed 429254]</a></p>\n<p>4. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9421":"<p><b>Title</b> Mecamylamine / Polymyxin B</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of mecamylamine and polymyxin B.</p> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking antibiotics should generally not be treated with mecamylamine.<sup>1</sup> Although not explicitly stated, this is likely due to the concern that certain antibiotics (ie, polymixins) and ganglionic blocking drugs (ie, mecamylamine) both exert neuromuscular blocking effects.<sup>1,2,3,4</sup> While data are lacking to support an increased risk of neuromuscular blockade when these agents are combined, one study in rats found that the combination of trimethaphan (another ganglionic blocking drug) and various aminoglycosides (an antibiotic class associated with neuromuscular blockade) produced complete neuromuscular blockade at concentrations achieved with usual therapeutic doses.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p>2. Fogdall RP, Miller RD. Prolongation of pancuronium-induced neuromuscular blockade by polymyxin B. <i>Anesthesiology</i>. 1974;40(1):84-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4359101\">[PubMed 4359101]</a></p>\n<p>3. Small GA. Report of a case: Respiratory paralysis after a large dose of intraperitoneal polymyxin B and bacitracin. <i>Anesth Analg</i>. 1964;43:137-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14164930\">[PubMed 14164930]</a></p>\n<p>4. Pohlmann G. Respiratory arrest associated with intravenous administration of polymyxin B sulfate. <i>JAMA</i>. 1966;196(2):181-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4286165\">[PubMed 4286165]</a></p>\n<p>5. Paradelis AG, Crassaris LG, Karachalios DN, Triantaphyllidis CJ. Aminoglycoside antibiotics: interaction with trimethaphan at the neuromuscular junctions. <i>Drugs Exp Clin Res</i>. 1987;13(4):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622253\">[PubMed 3622253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9422":"<p><b>Title</b> Mecamylamine / Sulfonamides</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of mecamylamine and sulfonamides.</p>\n<div>\n <p><b>Sulfonamides Interacting Members</b> AcetaZOLAMIDE, Bendroflumethiazide, Bumetanide, Celecoxib, Chlorothiazide, ChlorproPAMIDE, Chlorthalidone, Cyclopenthiazide, Furosemide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Nimesulide, Parecoxib, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, Sulfanilamide, SulfiSOXAZOLE, Sulthiame, TOLAZamide, TOLBUTamide, Torsemide, Xipamide</p>\n</div> \n<p><b>Discussion</b> Prescribing information for mecamylamine states that patients taking sulfonamides should generally not be treated with mecamylamine.<sup>1</sup> The reason for avoidance of this combination is not stated and a mechanism for a potential interaction is unclear. Some sulfonamide drugs are carbonic anhydrase inhibitors (eg, acetazolamide) and some are antibiotics whose safety is enhanced with the concomitant use of drugs that alkalinize the urine. Elevated urinary pH significantly reduces renal excretion of mecamylamine, but whether this is the reason for the interaction warning or if the warning is applicable to other sulfonamides that do not affect urinary pH is unknown.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vecamyl (mecamylamine) [prescribing information]. Colorado Springs, CO: Nexgen Pharma Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9423":"<p><b>Title</b> Vitamin K Antagonists / LevOCARNitine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LevOCARNitine may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Monitor anticoagulant response, including INR and signs/symptoms of bleeding, more closely when using levocarnitine together with vitamin K antagonists, particularly when starting or stopping levocarnitine.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A published case report describes a 62-year-old woman on stable doses of acenocoumarol (3 mg daily), furosemide, and digoxin who was admitted to the hospital for melena with an INR of 7 five days after initiation of levocarnitine.<sup>1</sup> Levocarnitine and acenocoumarol were subsequently discontinued, and fresh frozen plasma, vitamin K, and heparin were administered. On day 10, the patient was discharged on acenocoumarol at the previous dose with an INR of 2.1.<br><br>The levocarnitine prescribing information cautions about potential INR increases in patients using levocarnitine with warfarin-like products and recommends INR levels be carefully monitored after initiation of therapy or dose adjustments.<sup>2</sup> The mechanism of action is currently unknown; however, L-carnitine has been shown to modulate platelet activation and aggregation.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Martinez E, Domingo P, Roca-Cusachs A. Potentiation of acenocoumarol action by L-carnitine. <i>J Intern Med</i>. 1993;233(1):94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8429297\">[PubMed 8429297]</a></p>\n<p>2. Carnitor (levocarnitine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc; April 2015.</p>\n<p>3. Saluk-Juszczak J, Olas B, Wachowicz B, Glowacki R, Bald E. L-carnitine modulates blood platelet oxidative stress. <i>Cell Biol Toxicol</i>. 2010;26(4):355-365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20069352\">[PubMed 20069352]</a></p>\n<p>4. Pignatelli P, Lenti L, Sanguigni V, et al. Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress. <i>Am J Physiol Heart Circ Physiol</i>. 2003;284(1):H41-H48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12388290\">[PubMed 12388290]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9424":"<p><b>Title</b> Drospirenone / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Drospirenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the potential potassium-retaining properties of drospirenone, patients at higher risk for hyperkalemia who are also using another potassium-retaining drug (e.g., angiotensin-converting enzyme inhibitors) should be monitored for evidence of hyperkalemia during their first treatment cycle with drospirenone. Those at higher risk include, but are not limited to, those with impaired renal or hepatic function, adrenal insufficiency, or concurrent medications that may increase drospirenone concentrations.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The drospirenone prescribing information cautions that drospirenone has anti-mineralocorticoid activity (3 mg drospirenone is approximately similar to 25 mg of spironolactone) that may result in potassium retention and hyperkalemia in higher-risk patients, such as those with impaired renal or hepatic function or adrenal insufficiency.<sup>1,2,3</sup> As a result, caution is recommended with regular use of drospirenone-containing contraceptives together with other medications that can promote potassium retention (e.g., drugs working on the renin-angiotensin-aldosterone system, potassium-sparing diuretics, non-steroidal antiinflammatory drugs, etc.), particularly in patients who may have other risk factors for hyperkalemia.<br><br>Many clinical studies have shown no significant increase in the risk for hyperkalemia among women using drospirenone. A randomized, placebo-controlled trial of 82 diabetic women and 142 non-diabetic women receiving 3 mg drosperinone or placebo along with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker for 28 days showed no statistically or clinically significant differences in change from baseline in serum potassium.<sup>4</sup> A retrospective cohort study of 224,408 patients taking drosperinone found no significant difference in the risk of hyperkalemia with drospirenone as compared to levonorgestrel.<sup>5</sup> A matched cohort study with 67,287 women (22,429 receiving drospirenone) similarly found no difference in composite hyperkalemia outcomes (including syncope, arrhythmia, and other electrolyte disturbances) among drospirenone users as compared to any other oral contraceptive.<sup>6</sup> An open-label study of 11 women with normal renal function (CrCl greater than 80 mL/min), 10 with mild renal impairment (CrCl = 50-80 mL/min ), and 7 with moderate renal impairment (CrCl = 30-50 mL/min) found higher serum potassium concentrations in those with renal impairment, but no significant changes compared to baseline concentrations.<sup>7</sup> This included 3 subjects on ACE inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yaz (drospirenone and ethinyl estradiol) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; May 2015.</p>\n<p>2. Beyaz (drospirenone, ethinyl estradiol, levomefolate) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; June 2015.</p>\n<p>3. Angeliq (drospirenone and estradiol) [prescribing information]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc; February 2012.</p>\n<p>4. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. <i>Am J Hypertens</i>. 2005;18(6):797-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15925739\">[PubMed 15925739]</a></p>\n<p>5. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. <i>BMC Clin Pharmacol</i>. 2011;11:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22208934\">[PubMed 22208934]</a></p>\n<p>6. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. <i>Contraception</i>. 2008;78(5):377-383. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18929734\">[PubMed 18929734]</a></p>\n<p>7. Schurmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. <i>J Clin Pharmacol</i>. 2006;46(8):867-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855071\">[PubMed 16855071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9425":"<p><b>Title</b> Drospirenone / Angiotensin II Receptor Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Drospirenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the potential potassium-retaining properties of drospirenone, patients at higher risk for hyperkalemia who are also using another potassium-retaining drug (e.g., angiotensin receptor blockers) should be monitored for evidence of hyperkalemia during their first treatment cycle with drospirenone. Those at higher risk include, but are not limited to, those with impaired renal or hepatic function, adrenal insufficiency, or concurrent medications that may increase drospirenone concentrations.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> The drospirenone prescribing information cautions that drospirenone has anti-mineralocorticoid activity (3 mg drospirenone is approximately similar to 25 mg of spironolactone) that may result in potassium retention and hyperkalemia in higher-risk patients, such as those with impaired renal or hepatic function or adrenal insufficiency.<sup>1,2,3</sup> As a result, caution is recommended with regular use of drospirenone-containing contraceptives together with other medications that can promote potassium retention (e.g., drugs working on the renin-angiotensin-aldosterone system, potassium-sparing diuretics, non-steroidal antiinflammatory drugs, etc.), particularly in patients who may have other risk factors for hyperkalemia.<br><br>Many clinical studies have shown no significant increase in the risk for hyperkalemia among women using drospirenone. A randomized, placebo-controlled trial of 82 diabetic women and 142 non-diabetic women receiving 3 mg drosperinone or placebo along with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker for 28 days showed no statistically or clinically significant differences in change from baseline in serum potassium.<sup>4</sup> A retrospective cohort study of 224,408 patients taking drosperinone found no significant difference in the risk of hyperkalemia with drospirenone as compared to levonorgestrel.<sup>5</sup> A matched cohort study with 67,287 women (22,429 receiving drospirenone) similarly found no difference in composite hyperkalemia outcomes (including syncope, arrhythmia, and other electrolyte disturbances) among drospirenone users as compared to any other oral contraceptive.<sup>6</sup> An open-label study of 11 women with normal renal function (CrCl greater than 80 mL/min), 10 with mild renal impairment (CrCl = 50-80 mL/min ), and 7 with moderate renal impairment (CrCl = 30-50 mL/min) found higher serum potassium concentrations in those with renal impairment, but no significant changes compared to baseline concentrations.<sup>7</sup> This included 3 subjects on ACE inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yaz (drospirenone and ethinyl estradiol) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; May 2015.</p>\n<p>2. Beyaz (drospirenone, ethinyl estradiol, levomefolate) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; June 2015.</p>\n<p>3. Angeliq (drospirenone and estradiol) [prescribing information]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc; February 2012.</p>\n<p>4. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. <i>Am J Hypertens</i>. 2005;18(6):797-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15925739\">[PubMed 15925739]</a></p>\n<p>5. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. <i>BMC Clin Pharmacol</i>. 2011;11:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22208934\">[PubMed 22208934]</a></p>\n<p>6. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. <i>Contraception</i>. 2008;78(5):377-383. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18929734\">[PubMed 18929734]</a></p>\n<p>7. Schurmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. <i>J Clin Pharmacol</i>. 2006;46(8):867-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855071\">[PubMed 16855071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9426":"<p><b>Title</b> Aliskiren / Drospirenone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Drospirenone may enhance the hyperkalemic effect of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the potential potassium-retaining properties of drospirenone, patients at higher risk for hyperkalemia who are also using another potassium-retaining drug (e.g., aliskiren) should be monitored for evidence of hyperkalemia during their first treatment cycle with drospirenone. Those at higher risk include, but are not limited to, those with impaired renal or hepatic function, adrenal insufficiency, or concurrent medications that may increase drospirenone concentrations.</p> \n<p><b>Discussion</b> The drospirenone prescribing information cautions that drospirenone has anti-mineralocorticoid activity (3 mg drospirenone is approximately similar to 25 mg of spironolactone) that may result in potassium retention and hyperkalemia in higher-risk patients, such as those with impaired renal or hepatic function or adrenal insufficiency.<sup>1,2,3</sup> As a result, caution is recommended with regular use of drospirenone-containing contraceptives together with other medications that can promote potassium retention (e.g., drugs working on the renin-angiotensin-aldosterone system, potassium-sparing diuretics, non-steroidal antiinflammatory drugs, etc.), particularly in patients who may have other risk factors for hyperkalemia.<br><br>Many clinical studies have shown no significant increase in the risk for hyperkalemia among women using drospirenone. A randomized, placebo-controlled trial of 82 diabetic women and 142 non-diabetic women receiving 3 mg drosperinone or placebo along with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker for 28 days showed no statistically or clinically significant differences in change from baseline in serum potassium.<sup>4</sup> A retrospective cohort study of 224,408 patients taking drosperinone found no significant difference in the risk of hyperkalemia with drospirenone as compared to levonorgestrel.<sup>5</sup> A matched cohort study with 67,287 women (22,429 receiving drospirenone) similarly found no difference in composite hyperkalemia outcomes (including syncope, arrhythmia, and other electrolyte disturbances) among drospirenone users as compared to any other oral contraceptive.<sup>6</sup> An open-label study of 11 women with normal renal function (CrCl greater than 80 mL/min), 10 with mild renal impairment (CrCl = 50-80 mL/min ), and 7 with moderate renal impairment (CrCl = 30-50 mL/min) found higher serum potassium concentrations in those with renal impairment, but no significant changes compared to baseline concentrations.<sup>7</sup> This included 3 subjects on ACE inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yaz (drospirenone and ethinyl estradiol) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; May 2015.</p>\n<p>2. Beyaz (drospirenone, ethinyl estradiol, levomefolate) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; June 2015.</p>\n<p>3. Angeliq (drospirenone and estradiol) [prescribing information]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc; February 2012.</p>\n<p>4. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. <i>Am J Hypertens</i>. 2005;18(6):797-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15925739\">[PubMed 15925739]</a></p>\n<p>5. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. <i>BMC Clin Pharmacol</i>. 2011;11:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22208934\">[PubMed 22208934]</a></p>\n<p>6. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. <i>Contraception</i>. 2008;78(5):377-383. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18929734\">[PubMed 18929734]</a></p>\n<p>7. Schurmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. <i>J Clin Pharmacol</i>. 2006;46(8):867-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855071\">[PubMed 16855071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9427":"<p><b>Title</b> Drospirenone / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the potential potassium-retaining properties of drospirenone, patients at higher risk for hyperkalemia who are also using another potassium-retaining drug (e.g.,non-steroidal antiinflammatory drugs) should be monitored for evidence of hyperkalemia during their first treatment cycle with drospirenone. Those at higher risk include, but are not limited to, those with impaired renal or hepatic function, adrenal insufficiency, or concurrent medications that may increase drospirenone concentrations.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The drospirenone prescribing information cautions that drospirenone has anti-mineralocorticoid activity (3 mg drospirenone is approximately similar to 25 mg of spironolactone) that may result in potassium retention and hyperkalemia in higher-risk patients, such as those with impaired renal or hepatic function or adrenal insufficiency.<sup>1,2,3</sup> As a result, caution is recommended with regular use of drospirenone-containing contraceptives together with other medications that can promote potassium retention (e.g., drugs working on the renin-angiotensin-aldosterone system, potassium-sparing diuretics, non-steroidal antiinflammatory drugs, etc.), particularly in patients who may have other risk factors for hyperkalemia.<br><br>Many clinical studies have shown no significant increase in the risk for hyperkalemia among women using drospirenone. A randomized, placebo-controlled trial of 82 diabetic women and 142 non-diabetic women receiving 3 mg drosperinone or placebo along with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker for 28 days showed no statistically or clinically significant differences in change from baseline in serum potassium.<sup>4</sup> A retrospective cohort study of 224,408 patients taking drosperinone found no significant difference in the risk of hyperkalemia with drospirenone as compared to levonorgestrel.<sup>5</sup> A matched cohort study with 67,287 women (22,429 receiving drospirenone) similarly found no difference in composite hyperkalemia outcomes (including syncope, arrhythmia, and other electrolyte disturbances) among drospirenone users as compared to any other oral contraceptive.<sup>6</sup> An open-label study of 11 women with normal renal function (CrCl greater than 80 mL/min), 10 with mild renal impairment (CrCl = 50-80 mL/min ), and 7 with moderate renal impairment (CrCl = 30-50 mL/min) found higher serum potassium concentrations in those with renal impairment, but no significant changes compared to baseline concentrations.<sup>7</sup> This included 3 subjects on ACE inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yaz (drospirenone and ethinyl estradiol) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; May 2015.</p>\n<p>2. Beyaz (drospirenone, ethinyl estradiol, levomefolate) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; June 2015.</p>\n<p>3. Angeliq (drospirenone and estradiol) [prescribing information]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc; February 2012.</p>\n<p>4. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. <i>Am J Hypertens</i>. 2005;18(6):797-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15925739\">[PubMed 15925739]</a></p>\n<p>5. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. <i>BMC Clin Pharmacol</i>. 2011;11:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22208934\">[PubMed 22208934]</a></p>\n<p>6. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. <i>Contraception</i>. 2008;78(5):377-383. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18929734\">[PubMed 18929734]</a></p>\n<p>7. Schurmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. <i>J Clin Pharmacol</i>. 2006;46(8):867-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855071\">[PubMed 16855071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9428":"<p><b>Title</b> Drospirenone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the potential potassium-retaining properties of drospirenone, concurrent use with strong inhibitors of CYP3A4 should be considered with caution as the impact of higher drospirenone concentrations on risks for hyperkalemia are uncertain. Patients at higher risk for hyperkalemia should be monitored for evidence of hyperkalemia during their first treatment cycle exposed to this combination. Those at higher risk include, but are not limited to, those with impaired renal or hepatic function, adrenal insufficiency, or concurrent use of other medications that have potassium-retaining properties.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The drospirenone AUC was an average of 2.7-fold higher with concurrent use of the strong CYP3A inhibitor ketoconazole in a study where subjects received drospirenone 3 mg/ethinyl estradiol 0.02 mg daily with ketoconazole 200 mg twice daily for 10 days.<sup>1,2</sup> No significant adverse effects were noted, though it was emphasized that follow-up was limited to the 10-day study period.<br><br>The likely mechanism for this interaction is inhibition of the CYP3A-mediated metabolism of drospirenone by ketoconazole.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yaz (drospirenone and ethinyl estradiol) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; May 2015.</p>\n<p>2. Beyaz (drospirenone, ethinyl estradiol, levomefolate) [prescribing information]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9429":"<p><b>Title</b> Zoster Vaccine (Live/Attenuated) / Fingolimod</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fingolimod may enhance the adverse/toxic effect of Zoster Vaccine (Live/Attenuated). The risk of herpes zoster infection may be increased. Fingolimod may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of the live zoster vaccine during fingolimod treatment, and for 2 months following treatment discontinuation, due to an elevated risk of infection. Additionally, wait 1 month after zoster vaccine administration to initiate fingolimod therapy to allow the full effect of vaccination to occur.</p> \n<p><b>Discussion</b> Life-threatening and fatal cases of herpes zoster infection have been documented in patients receiving fingolimod.<sup>1</sup> Patients who are varicella zoster virus (VSV) antibody negative (or who do not have documentation of VSV vaccination or a chickenpox infection) should receive the zoster vaccine at least 1 month prior to initiating fingolimod therapy.<sup>1</sup> One case report describes a 36-year-old VSV antibody negative woman who received fingolimod for 5 days.<sup>2</sup> After discovering she was VSV antibody negative, fingolimod was discontinued and she received the zoster vaccine one day later.<sup>2</sup> She did not experience any systemic zoster infection, but her 3-year-old daughter developed a varicella infection 14 days later. After 30 days, fingolimod was restarted and within 1 year she experienced 2 separate episodes of thoracic shingles.<sup>2</sup><br><br>Prescribing information for fingolimod recommends avoiding all live attenuated vaccines during treatment, and for 2 months following treatment, due to a possible increased risk of infection.<sup>1</sup> Additionally, fingolimod treatment is associated with decreases in circulating lymphocytes and neutrophils, resulting in a blunted response to vaccines, so initiation of fingolimod should occur at least 1 month after zoster vaccine administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2015.</p>\n<p>2. Berger JR. Varicella vaccination after fingolimod: A case report. <i>Mult Scler Relat Disord</i>. 2013;2(4):391-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25877852\">[PubMed 25877852]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9430":"<p><b>Title</b> MedroxyPROGESTERone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of MedroxyPROGESTERone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased medroxyprogesterone effects/toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Clarithromycin, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), MiFEPRIStone, Nefazodone, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Telithromycin, Voriconazole<br><b>Exceptions</b> Atazanavir, Boceprevir, Cobicistat, Darunavir, Lopinavir, Nelfinavir, Saquinavir, Telaprevir</p>\n</div> \n<p><b>Discussion</b> Prescribing information for depo-medroxyprogesterone acetate (DMPA) states that since medroxyprogesterone has been shown to be a substrate of CYP3A4 in vitro, use with strong inhibitors of CYP3A4 should be avoided.<sup>1</sup> <br><br>In contrast to this statement, one study of HIV-infected women found that patients who received DMPA (150 mg every 3 months) while taking a nelfinavir-based regimen (1,250 mg twice daily or 750 mg three times daily) (n = 22) had a similar medroxyprogesterone AUC, maximum serum concentration (Cmax), and minimum serum concentration (Cmin) compared with those who received DMPA and efavirenz, nevirapine, or no antiretroviral therapy.<sup>2</sup> Progesterone levels remained low (less than 5 ng/mL), suggesting no ovulation occurred, and no pregnancies were reported.<sup>3</sup> Another pharmacokinetic study of 24 HIV-infected women reported that the medroxyprogesterone AUC and Cmax was 70% and 89% higher, respectively, when DMPA (150 mg single dose) was combined with lopinavir/ritonavir (400 mg/100 mg twice daily) compared with historical controls.<sup>4</sup> There was no difference in the medroxyprogesterone Cmin between groups.<sup>4</sup> The increased medroxyprogesterone exposure was well tolerated and thought to be clinically insignificant.<sup>4</sup> Clinical guidelines state that DMPA and protease inhibitors (ie, strong CYP3A4 inhibitors) can be safely combined.<sup>5</sup> Prescribing information for oral medroxyprogesterone products states that concomitant use with strong CYP3A4 inhibitors may result in increased medroxyprogesterone concentrations and effects, but does not recommend avoidance of the combination.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Depo-Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer Inc; June 2015.</p>\n<p>2. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. <i>Clin Pharmacol Ther</i>. 2007;81(2):222-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17192768\">[PubMed 17192768]</a></p>\n<p>3. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. <i>Contraception</i>. 2008;77(2):84-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18226670\">[PubMed 18226670]</a></p>\n<p>4. Luque AE, Cohn SE, Park JG, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. <i>Antimicrob Agents Chemother</i>. 2015;59(4):2094-2101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25624326\">[PubMed 25624326]</a></p>\n<p>5. HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed June 18, 2015.</p>\n<p>6. Prempro (conjugated estrogens/medroxyprogesterone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2012.</p>\n<p>7. Provera (medroxyprogesterone) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9431":"<p><b>Title</b> Progesterone / Antifungal Agents (Vaginal)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the vaginal progesterone product (Endometrin) and vaginal antifungal products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients using a progesterone vaginal insert (Endometrin), avoid the use of vaginal antifungal agents.</p>\n<div>\n <p><b>Antifungal Agents (Vaginal) Interacting Members</b> Butoconazole, Clotrimazole (Topical), Fenticonazole, Isoconazole, Miconazole (Topical), Nystatin (Topical), Sertaconazole, Sulfanilamide, Terconazole, Tioconazole</p>\n</div> \n<p><b>Discussion</b> The prescribing information for the progesterone vaginal insert states that the effect of concomitant vaginal products (such as antifungal products) on the exposure of progesterone has not been assessed, but it may alter progesterone release and absorption from the vaginal insert.<sup>1,2</sup> Concomitant use is not recommended.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Endometrin (progesterone) vaginal insert [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; February 2008.</p>\n<p>2. Endometrin (progesterone) vaginal tablets [product monograph]. North York, Ontario, Canada: Ferring Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9432":"<p><b>Title</b> Clopidogrel / Cangrelor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cangrelor may diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopidogrel, Cangrelor is expected to decrease binding of Clopidogrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid administration of clopidogrel until cangrelor is discontinued.</p> \n<p><b>Discussion</b> In a clinical study of 20 healthy volunteers, administration of clopidogrel (600 mg single oral dose) during a cangrelor infusion (30 ug/kg bolus, then 4 ug/kg/min for 2 hours) substantially reduced the extent of platelet inhibition post-infusion compared with clopidogrel given at the end of infusion and compared with the time course of platelet inhibition by clopidogrel given alone.<sup>2</sup> <br><br>The suspected mechanism of this interaction is cangrelor (a reversible P2Y12 inhibitor) inhibition of irreversible P2Y12 binding and platelet inhibition by clopidogrel metabolites. Consistent with this mechanism, in vitro studies have characterized a substantial reduction in the extent of irreversible platelet inhibition by clopidogrel metabolites with cangrelor pretreatment<sup>2</sup> and an increase in total platelet inhibition when cangrelor was added to platelet-rich plasma samples from patients pretreated with clopidogrel.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. <i>Thromb Res</i>. 2008;121(4):527-534. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17631948\">[PubMed 17631948]</a></p>\n<p>2. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. <i>J Thromb Haemost</i>. 2008;6(7):1153-1159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18485086\">[PubMed 18485086]</a></p>\n<p>3. Bouman HJ, van Werkum JW, Hackeng CM, Clappers N, Ten Berg JM. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. <i>Neth Heart J</i>. 2009;17(5):195-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19484155\">[PubMed 19484155]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9433":"<p><b>Title</b> Prasugrel / Cangrelor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cangrelor may diminish the antiplatelet effect of Prasugrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Prasugrel, Cangrelor is expected to decrease binding of Prasugrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid administration of prasugrel until cangrelor is discontinued.</p> \n<p><b>Discussion</b> US prescribing information recommends not administering prasugrel during cangrelor infusion due to the expected reduction in prasugrel antiplatelet effects.<sup>1</sup><br><br>In a clinical study, 15 adults with stable coronary artery disease and receiving aspirin were given cangrelor (30 ug/kg bolus, then 4 ug/kg/min for 2 hours) in combination with prasugrel (60 mg single oral dose) 1 hour, 1.5 hours, or 2.5 hours after the start of infusion.<sup>2</sup> Although all regimens were associated with a rebound in platelet reactivity following the end of cangrelor infusion, the lowest maximal rebound (mean platelet aggregation around 40% measured by light transmission aggregometry) was seen with prasugrel given 1.5 hours after the start of infusion. Aggregation measured 5.5 hours after the start of infusion (ie, 3.5 hours after the end of infusion) was similar to that seen during cangrelor infusion with all regimens. No clear impact of prasugrel on cangrelor pharmacodynamics was seen when cangrelor infusion was repeated after patients received prasugrel (10 mg orally daily) for 5 to 6 days.<br><br>The suspected mechanism of this interaction is cangrelor (a reversible P2Y12 inhibitor) inhibition of irreversible P2Y12 binding and platelet inhibition by prasugrel metabolites. Consistent with this mechanism, in vitro studies have characterized a substantial reduction in the extent of irreversible platelet inhibition by prasugrel metabolites with cangrelor pretreatment<sup>3</sup> and an increase in total platelet inhibition when cangrelor was added to whole blood samples from patients pretreated with prasugrel.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kengreal (cangrelor) [prescribing information]. Parsippany, NJ: The Medicines Company; June 2015.</p>\n<p>2. Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. <i>Coron Artery Dis</i>. 2015;26(1):42-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25089928\">[PubMed 25089928]</a></p>\n<p>3. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. <i>J Thromb Haemost</i>. 2008;6(7):1153-1159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18485086\">[PubMed 18485086]</a></p>\n<p>4. Rollini F, Franchi F, Tello-Montoliu A, et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. <i>JACC Cardiovasc Interv</i>. 2014;7(4):426-434. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24630878\">[PubMed 24630878]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9434":"<p><b>Title</b> Cardiac Glycosides / Edrophonium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Edrophonium may enhance the AV-blocking effect of Cardiac Glycosides. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when administering edrophonium to patients receiving digoxin or other cardiac glycosides. Continuous electrocardiographic monitoring and means for resuscitation should be available.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> One case report describes an 81-year-old receiving digoxin who experienced AV block, a substantially decreased ventricular rate, and loss-of-consciousness during a 10 second period of asystole within two minutes of edrophonium (10 mg intravenously) administration.<sup>1</sup> Another case report describes a 66-year-old who was receiving digoxin for heart failure who experienced sinus bradycardia with ventricular asystole shortly after receiving edrophonium 10 mg intravenously.<sup>2</sup><br><br>Edrophonium is a rapidly acting inhibitor of cholinesterase that alters cardiac conduction by potentiating the effects of acetylcholine and vagal stimulation.<sup>3</sup> Reported complications of edrophonium have included sinus slowing, increased AV block, and ventricular asystole. Digoxin is a potent vagomimetic agent, and also slows heart rate and decreases conduction velocity through the AV node. As such, it is likely that digoxin may have potentiated the effects of edrophonium, leading to adverse cardiac effects.<br><br>The prescribing information for Enlon-Plus (edrophonium chloride and atropine sulfate) warns that cardiac arrest has been reported in patients receiving cardiac glycosides.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gould L, Zahir M, Gomprecht RF. Cardiac arrest during edrophonium administration. <i>Am Heart J</i>. 1971;81(3):437-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4251179\">[PubMed 4251179]</a></p>\n<p>2. Rossen RM, Krikorian J, Hancock EW. Ventricular asystole after edrophonium chloride administration. <i>JAMA</i>. 1976;235(10):1041-1042. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=765513\">[PubMed 765513]</a></p>\n<p>3. Enlon-Plus (edrophonium chloride and atropine sulfate) injection [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9435":"<p><b>Title</b> OLANZapine / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of OLANZapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination for reduced clinical effects of olanzapine.</p> \n<p><b>Discussion</b> In a clinical study of 14 healthy volunteers, ritonavir (300 mg twice daily for 3 days, then 400 mg twice daily for 4 days, then 500 mg twice daily for 4 days) reduced the olanzapine (10 mg single oral dose) maximum concentration (Cmax), AUC, and half-life by 40%, 53%, and 50%, respectively.<sup>1</sup> In a study of 20 healthy volunteers, fosamprenavir/ritonavir (700 mg/100 mg orally twice daily for 16 days) reduced the dose-adjusted olanzapine (15 mg single oral dose with fosamprenavir/ritonavir or 10 mg single oral dose alone) Cmax and AUC by 12% and 33%, respectively, and decreased its half-life by 32%.<sup>2</sup><br><br>The suspected primary mechanism of these interactions is ritonavir induction of CYP1A2- and/or glucuronosyltransferase-mediated olanzapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. <i>J Clin Psychopharmacol</i>. 2002;22(4):366-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12172335\">[PubMed 12172335]</a></p>\n<p>2. Jacobs BS, Colbers AP, Velthoven-Graafland K, Schouwenberg BJ, Burger DM. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. <i>Int J Antimicrob Agents</i>. 2014;44(2):173-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24929949\">[PubMed 24929949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9436":"<p><b>Title</b> GlyBURIDE / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of GlyBURIDE. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 9 healthy volunteers, simultaneous coadministration of verapamil (120 mg single oral dose) increased the glyburide (5 mg single oral dose) maximum concentration and AUC by 26% and 27%, respectively, without altering its impact on plasma glucose, C-peptide, insulin, or glucagon.<sup>1</sup> <br><br>The mechanism of this interaction is unclear, but may involve verapamil inhibition of glyburide metabolism (eg, via CYP2C9) and/or transport (eg, via P-glycoprotein).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Semple CG, Omile C, Buchanan KD, Beastall GH, Paterson KR. Effect of oral verapamil on glibenclamide stimulated insulin secretion. <i>Br J Clin Pharmacol</i>. 1986;22(2):187-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3092851\">[PubMed 3092851]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9437":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Morniflumate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Morniflumate may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of morniflumate with other nonsteroidal anti-inflammatory drugs.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Morniflumate Korean prescribing information states that its use should be avoided in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs).<sup>1</sup> Concurrent use of multiple NSAIDs is expected to increase the risk of some adverse effects, including gastrointestinal adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morniflu (morniflumate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200400514. Accessed September 12, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9438":"<p><b>Title</b> Morniflumate / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Morniflumate. Specifically, consumption of more than 3 alcoholic drinks per day may increase the risk of gastrointestinal hemorrhage during Morniflumate treatment. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to limit alcohol consumption during morniflumate treatment. Consumption of more than 3 alcoholic drinks per day may increase the risk of gastrointestinal hemorrhage.</p> \n<p><b>Discussion</b> Morniflumate Korean prescribing information states that the risk of gastrointestinal hemorrhage may increase in patients who consume alcohol, particularly in those who regularly consume more than 3 alcoholic drinks per day.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Morniflu (morniflumate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200400514. Accessed September 12, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9464":"<p><b>Title</b> Sacubitril / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of sacubitril/valsartan and an angiotensin-converting enzyme (ACE) inhibitor is contraindicated due to the risk of angioedema. Do not administer sacubitril/valsartan within 36 hours of switching to or from an ACE inhibitor.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Prescribing information for sacubitril/valsartan states that concomitant use with an angiotensin-converting enzyme (ACE) inhibitor is contraindicated due to the increased risk of angioedema.<sup>1</sup> Administration of sacubitril/valsartan and an ACE inhibitor should be separated by at least 36 hours.<sup>1</sup> Although the combination of an ACE inhibitor and sacubitril has not been studied, in clinical trials of omapatrilat (a combined neprilysin and ACE inhibitor) versus the ACE inhibitor enalapril, the risk of angioedema was greater with omapatrilat compared with the use of enalapril alone.<sup>2,3</sup><br><br>The increased risk of angioedema is thought to be due to increased bradykinin accumulation; both ACE and neprilysin are involved in bradykinin elimination.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Entresto (sacubitril/valsartan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.</p>\n<p>2. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. <i>Am J Hypertens</i>. 2004;17(2):103-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14751650\">[PubMed 14751650]</a></p>\n<p>3. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). <i>Circulation</i>. 2002;106(8):920-926. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12186794\">[PubMed 12186794]</a></p>\n<p>4. McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. <i>Eur J Heart Fail</i>. 2015;17(3):242-247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25756942\">[PubMed 25756942]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9465":"<p><b>Title</b> Meperidine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Meperidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased meperidine effects/toxicities when combined with cimetidine. Use of an alternative H2-receptor antagonist, such as ranitidine, may avoid this interaction.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, cimetidine (600 mg twice daily x 7 days) decreased the meperidine (70 mg single intravenous dose) clearance 22%.<sup>1</sup> The AUC and maximum serum concentration of normeperidine (the neurotoxic metabolite) were decreased 23% and 29%, respectively.<sup>1</sup> In a case series of meperidine-induced delirium, cimetidine was a concomitant medication in 3 of 6 cases (50%).<sup>2</sup> As an alternative, the H2-receptor antagonist ranitidine (150 mg twice daily x 7 days) had no effect on the pharmacokinetics of meperidine (70 mg single intravenous dose) or normeperidine.<sup>3</sup><br><br>The mechanism of this interaction is unknown, but cimetidine inhibition of hepatic enzymes responsible for meperidine metabolism may play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. <i>Br J Clin Pharmacol</i>. 1984;18(6):907-914. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6529532\">[PubMed 6529532]</a></p>\n<p>2. Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. <i>Am J Psychiatry</i>. 1987;144(8):1062-1065. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3605428\">[PubMed 3605428]</a></p>\n<p>3. Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. <i>Br J Clin Pharmacol</i>. 1985;20(1):55-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4027136\">[PubMed 4027136]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9466":"<p><b>Title</b> Moclobemide / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Moclobemide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The concomitant use of moclobemide and any other monoamine oxidase inhibitor is contraindicated. This includes the use of nonselective agents (eg, linezolid) and MAO-B inhibitors (eg, selegiline).</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The product monograph for moclobemide states that concomitant use with any monoamine oxidase inhibitor is contraindicated.<sup>1</sup> The combination of selegiline and moclobemide resulted in supra-additive tyramine sensitivity.<sup>1</sup> While the concomitant use of most other monoamine oxidase inhibitors and moclobemide has not been studied, their combination is still contraindicated due to the risk of serotonin syndrome and/or hypertensive crisis.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9467":"<p><b>Title</b> Clemastine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced or prolonged anticholinergic effects of clemastine in patients receiving monoamine oxidase inhibitors (MAOIs). The manufacturer of one clemastine product lists its use in combination with MAOIs as contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Methylene Blue, Moclobemide, Phenelzine, Syrian Rue, Tranylcypromine<br><b>Exceptions</b> Linezolid, Procarbazine, Rasagiline, Safinamide, Selegiline, Tedizolid</p>\n</div> \n<p><b>Discussion</b> The concomitant use of a monoamine oxidase inhibitor (MAOI) with clemastine may increase the duration or severity of anticholinergic effects compared with the use of either drug alone. US prescribing information for one clemastine product lists use with MAOIs as contraindicated due to the potential for these increased effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Clemastine [prescribing information]. Princeton, NJ: Sandoz Inc; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9468":"<p><b>Title</b> QUEtiapine / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of QUEtiapine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative to this combination when possible. The ritonavir Canadian product monograph cautions that this combination should not be used. U.S. ritonavir labeling recommends using an alternative when possible, but that if the combination must be used, to reduce the quetiapine dose to one-sixth of the original quetiapine dose and then to monitor response to therapy. If discontinuing ritonavir in a patient using this combination, a corresponding increase in quetiapine dose may be needed.</p> \n<p><b>Discussion</b> Specific pharmacokinetic data concerning this interaction are not available, but the ritonavir Canadian product monograph states that serious and life-threatening adverse reactions with the combination have been reported.<sup>1</sup><br><br>The suspected mechanism for this predicted interaction is inhibition of the CYP3A-mediated quetiapine metabolism by ritonavir, which is a strong CYP3A4 inhibitor. In a clinical study summarized in quetiapine U.S. prescribing information, coadministraiton of the strong CYP3A4 inhibitor ketoconazole (200 mg daily for 4 days) was associated with an average 3.4- and 6.2-fold increase in the maximum serum concentration and AUC of quetiapine (25 mg single dose), respectively.<sup>2,3,4</sup> Additionally, several published case reports describe adverse clinical effects (weight gain, sedation, confusion, respiratory depression) and/or prolonged quetiapine elimination (estimated half-life over 62 hours in a patient following overdose) in patients receiving quetiapine during or proximate to use of strong CYP3A4 inhibitors.<sup>5,6,7,8</sup> A retrospective review of therapeutic drug monitoring data also detected a non-significant 71% greater median quetiapine serum concentration/dose ratio in patients receiving concurrent drugs that interact with CYP3A4, although the exact agents included in this analysis are not defined and the authors state that only 1 patient received a “high affinity” CYP3A4 inhibitor (nefazodone).<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvir (ritonavir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; May 2015.</p>\n<p>2. Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2013.</p>\n<p>3. Seroquel XR (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2013.</p>\n<p>4. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 2006;61(1):58-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390352\">[PubMed 16390352]</a></p>\n<p>5. Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. <i>Drug Metab Lett</i>. 2010;4(1):7-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20201782\">[PubMed 20201782]</a></p>\n<p>6. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. <i>Pharmacotherapy</i>. 2009;29(11):1386-1391. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19857154\">[PubMed 19857154]</a></p>\n<p>7. Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. <i>Pharmacopsychiatry</i>. 2008;41(6):258-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19067264\">[PubMed 19067264]</a></p>\n<p>8. Worthley DL, Burgess N, Nigro O, Shakib S. Seroquel, Serzone and seizures. <i>Intern Med J</i>. 2004;34(3):134-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15030464\">[PubMed 15030464]</a></p>\n<p>9. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. <i>Ther Drug Monit</i>. 2004;26(5):486-491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385830\">[PubMed 15385830]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9469":"<p><b>Title</b> CYP2B6 Substrates (High risk with Inducers) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to any CYP2B6 substrates closely when used with lumacaftor. Drugs inactivated by CYP2B6 may have decreased effectiveness, while any drugs activated by CYP2B6 may exhibit increased effects or toxicity.</p>\n<div>\n <p><b>CYP2B6 Substrates (High risk with Inducers) Interacting Members</b> BuPROPion, Cyclophosphamide, Efavirenz, Ifosfamide, Methadone, Selegiline, Velpatasvir</p>\n</div> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that lumacaftor was shown to be a potential CYP2B6 inducer in vitro.<sup>1</sup> As a result, lumacaftor may alter concentrations and effects of CYP2B6 substrates through induction of CYP2B6-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9471":"<p><b>Title</b> CYP2C9 Substrates (High Risk with Inhibitors or Inducers) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to any CYP2C9 substrates closely when used with lumacaftor. Drug effects may be increased or decreased.</p>\n<div>\n <p><b>CYP2C9 Substrates (High Risk with Inhibitors or Inducers) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, Dapsone (Systemic), Etravirine, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Ketamine, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Ospemifene, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin, Zafirlukast</p>\n</div> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that in vitro studies showed that lumacaftor could act as an inducer and/or inhibitor of CYP2C9.<sup>1</sup> As a result, lumacaftor may alter concentrations and effects of CYP2C9 substrates through induction and/or inhibition of CYP2C9-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9472":"<p><b>Title</b> CYP2C19 Substrates (High risk with Inducers) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to any CYP2C19 substrates closely when used with lumacaftor. Drugs inactivated by CYP2C19 may have decreased effectiveness, while any drugs activated by CYP2C19 may exhibit increased effects or toxicity.</p>\n<div>\n <p><b>CYP2C19 Substrates (High risk with Inducers) Interacting Members</b> Bortezomib, Brivaracetam, Carisoprodol, Citalopram, CloBAZam, ClomiPRAMINE, Desogestrel, DiazePAM, Dydrogesterone, Escitalopram, Esomeprazole, Etizolam, Etravirine, Fosphenytoin, Imipramine, Lansoprazole, Methsuximide, Moclobemide, Nelfinavir, Nilutamide, Omeprazole, Pantoprazole, PHENobarbital, Phenytoin, Progesterone, RABEprazole, Stiripentol, Trimipramine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that lumacaftor was shown to be a potential CYP2C19 inducer in vitro.<sup>1</sup> As a result, lumacaftor may alter concentrations and effects of CYP2C19 substrates through induction of CYP2C19-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9473":"<p><b>Title</b> P-glycoprotein/ABCB1 Substrates / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to any p-glycoprotein substrates closely when used with lumacaftor. Drug effects may be increased or decreased.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Substrates Interacting Members</b> Afatinib, Aliskiren, Amiodarone, AtorvaSTATin, Betrixaban, Bilastine, Brentuximab Vedotin, Carfilzomib, Carvedilol, Celiprolol, Ceritinib, Cetirizine (Systemic), Cimetidine, Colchicine, Crizotinib, CycloSPORINE (Systemic), Dabigatran Etexilate, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Desloratadine, Dexamethasone (Systemic), Digitoxin, Digoxin, DilTIAZem, DOCEtaxel, DOXOrubicin (Conventional), Edoxaban, Erythromycin (Systemic), Estradiol (Systemic), Estradiol (Topical), Etoposide, Etoposide Phosphate, Everolimus, Fexofenadine, Fosamprenavir, Hydrocortisone (Systemic), IDArubicin, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Ivermectin (Systemic), Lapatinib, Ledipasvir, Linagliptin, Loperamide, Loperamide Oxide, Loratadine, Lovastatin, Methotrexate, MitoMYcin (Systemic), Morphine (Liposomal), Morphine (Systemic), Nadolol, Naldemedine, Naloxegol, Nelfinavir, NiCARdipine, Nintedanib, Ondansetron, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Paliperidone, PAZOPanib, QuiNIDine, QuiNINE, RaNITIdine, Ranolazine, RifAMPin, Riociguat, RisperiDONE, Ritonavir, RomiDEPsin, Saquinavir, SAXagliptin, Silodosin, Sirolimus, SITagliptin, Sofosbuvir, Tacrolimus (Systemic), Telaprevir, Temsirolimus, Teniposide, Tolvaptan, Trabectedin, Vemurafenib, Venetoclax, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that in vitro studies showed that lumacaftor could act as an inhibitor of p-glycoprotein and an activator of the pregnane X receptor (PXR), which is a nuclear receptor that increases expression of p-glycoprotein (and several drug metabolizing enzymes).<sup>1</sup> As a result, lumacaftor may alter concentrations and effects of p-glycoprotein substrates through induction and/or inhibition of p-glycoprotein-mediated transport.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9474":"<p><b>Title</b> Itraconazole / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of lumacaftor and itraconazole is not recommended. Concurrent use with ketoconazole, posaconazole, or voriconazole is similarly not recommended. Consider an alternative antifungal such as fluconazole if appropriate. If this combination can not be avoided, monitor patient closely for evidence of decreased clinical response to itraconazole.</p> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that concurrent use with itraconazole, ketoconazole, posaconazole, or voriconazole is not recommended due to the potential for lumacaftor to reduce the concentrations and effectiveness of these antifungal agents.<sup>1</sup> The specific mechanism for the interaction varies among the antifungals, but for itraconazole and ketoconazole it is likely induction of their CYP3A4-mediated metabolism by lumacaftor, which is a strong CYP3A4 inducer.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9475":"<p><b>Title</b> Ketoconazole (Systemic) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of lumacaftor and ketoconazole is not recommended. Concurrent use with itraconazole, posaconazole, or voriconazole is similarly not recommended. Consider an alternative antifungal such as fluconazole if appropriate. If this combination can not be avoided, monitor patient closely for evidence of decreased clinical response to ketoconazole.</p> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that concurrent use with itraconazole, ketoconazole, posaconazole, or voriconazole is not recommended due to the potential for lumacaftor to reduce the concentrations and effectiveness of these antifungal agents.<sup>1</sup> The specific mechanism for the interaction varies among the antifungals, but for itraconazole and ketoconazole it is likely induction of their CYP3A4-mediated metabolism by lumacaftor, which is a strong CYP3A4 inducer.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9476":"<p><b>Title</b> Posaconazole / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Posaconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of lumacaftor and posaconazole is not recommended. Concurrent use with ketoconazole, itraconazole, or voriconazole is similarly not recommended. Consider an alternative antifungal such as fluconazole if appropriate. If this combination can not be avoided, monitor patient closely for evidence of decreased clinical response to posaconazole.</p> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that concurrent use with itraconazole, ketoconazole, posaconazole, or voriconazole is not recommended due to the potential for lumacaftor to reduce the concentrations and effectiveness of these antifungal agents.<sup>1</sup> The specific mechanism for the interaction varies among the antifungals, but for posaconazole it is likely induction of its p-glycoprotein-mediated transport by lumacaftor or possibly induction of its glucuronidation, although it is not known if lumacaftor, which is a strong CYP3A4 inducer and a possible inducer of several other metabolic enzymes, is capable of inducing glucuronidation or other phase II metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9477":"<p><b>Title</b> Voriconazole / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Voriconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of lumacaftor and voriconazole is not recommended. Concurrent use with ketoconazole, posaconazole, or itraconazole is similarly not recommended. Consider an alternative antifungal such as fluconazole if appropriate. If this combination can not be avoided, monitor patient closely for evidence of decreased clinical response to voriconazole.</p> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that concurrent use with itraconazole, ketoconazole, posaconazole, or voriconazole is not recommended due to the potential for lumacaftor to reduce the concentrations and effectiveness of these antifungal agents.<sup>1</sup> The specific mechanism for the interaction varies among the antifungals, but for voriconazole it is likely induction of CYP2C9, CYP2C19, and CYP3A4, all of which participate in voriconazole metabolism, by lumacaftor, which is a strong CYP3A4 inducer and a possible inducer of CYP2C9 and CYP2C19.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9478":"<p><b>Title</b> Montelukast / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Montelukast. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of reduced clinical effectiveness of montelukast if used together with lumacaftor.</p> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that concurrent use with montelukast may result in decreased concentrations and effectiveness of montelukast.<sup>1</sup> Specific data concerning this combination are not available, but based on the known pharmacology of these drugs, this is predicted to be a possible concern. The specific mechanism for the interaction is likely induction of CYP2C8, CYP2C9, and CYP3A4, all of which participate in montelukast metabolism, by lumacaftor, which is a strong CYP3A4 inducer and a possible inducer of CYP2C8 and CYP2C9.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9480":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not rely on hormone-based contraceptives with concurrent use of lumacaftor/ivacaftor. All hormonal contraceptive products, including both oral and non-oral products, are likely to be similarly subject to this interaction. An alternative, non-hormonal, method of contraception should be used if this combination is required. Monitor patients closely for evidence of menstruation-related adverse effects.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> The lumacaftor/ivacaftor prescribing information cautions that hormonal contraceptives may not be an effective means of contraception with concurrent lumacaftor/ivacaftor.<sup>1</sup> Although specific pharmacokinetic data concerning this potential interaction are not presented, the prescribing information reports that the incidence of menstruation-related adverse effects in lumacaftor/ivacaftor recipients was higher among those women also receiving hormonal contraceptives than among those not receiving hormonal contraceptives (27% vs. 3%), a difference that was attributed, at least in part, to increased estrogen metabolism by lumacaftor.<br><br>The proposed primary mechanism of this interaction is induction of the CYP3A4-mediated metabolism of estrogen contraceptives.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9481":"<p><b>Title</b> Progestins (Contraceptive) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lumacaftor may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not rely on hormone-based contraceptives with concurrent use of lumacaftor/ivacaftor. All hormonal contraceptive products, including both oral and non-oral products, are likely to be similarly subject to this interaction. An alternative, non-hormonal, method of contraception should be used if this combination is required. Monitor patients closely for evidence of menstruation-related adverse effects.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The lumacaftor/ivacaftor prescribing information cautions that hormonal contraceptives may not be an effective means of contraception with concurrent lumacaftor/ivacaftor.<sup>1</sup> Although specific pharmacokinetic data concerning this potential interaction are not presented, the prescribing information reports that the incidence of menstruation-related adverse effects in lumacaftor/ivacaftor recipients was higher among those women also receiving hormonal contraceptives than among those not receiving hormonal contraceptives (27% vs. 3%), a difference that was attributed, at least in part, to increased estrogen/progestin metabolism by lumacaftor.<br><br>The proposed primary mechanism of this interaction is induction of the CYP3A4-mediated metabolism of progestin contraceptives.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9482":"<p><b>Title</b> Anticoagulants / Vitamin E (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin E (Systemic) may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects (i.e., signs/symptoms of bleeding, INR, other tests of drug effectiveness, etc.) of anticoagulant if vitamin E is initiated/dose increased. Likely of significantly greater concern with higher doses of vitamin E.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> A warfarin-treated patient exhibited a prolonged prothrombin time (PT) and began to bleed within 2 months of initiating vitamin E therapy (1200 IU/day).<sup>1</sup> A subsequent challenge with 800 IU of vitamin E daily (for 7 weeks) showed a 41% increase in prothrombin time at 7 weeks (changes began at week 4), the development of ecchymoses on extremities, and decreased serum concentrations of blood clotting factors. Warfarin serum concentrations remained unchanged. The patient's coagulation status (including signs of over-anticoagulation) normalized within one week of discontinuing the vitamin E. The prothrombin activity (36 hours postdose) in 3 dicumarol-treated (150 mg single dose) healthy subjects was decreased from 52% to 33% when administered following a 30-day course of vitamin E (42 IU/day).<sup>2</sup> In contrast, two studies involving 37 patients showed no significant changes in response to warfarin during concomitant administration of vitamin E (doses up to 1200 IU/day).<sup>3,4</sup><br><br>The specicfic mechanism(s) of this interaction is unknown. One author group has postulated that vitamin E may interfere with the vitamin K-dependent process of clotting factor production.<sup>5</sup> Another suspected mechanism is vitamin E inhibition of monocyte expression of tissue factor, which is a glycoprotein that converts factor X to Xa (specifically in cirrhotic patients).<sup>6</sup> It is plausible that vitamin E may affect the coagulation cascade and have the potential to potentiate the anticoagulant effects of various anticoagulants. A systematic review found mixed results on the incidence of hemorrhagic stroke associated with vitamin E intake (independent of anticoagulant use).<sup>7</sup> From the trials included, the subjects were varied and included healthy US women,<sup>8</sup> at-risk female health professionals,<sup>9</sup> and subjects at high risk for cardiovascular events who were not at increased risk of hemorrhagic stroke associated with vitamin E.<sup>10</sup> On the other hand, male smokers from the ATBC Trial had increased incidence of fatal hemorrhagic stroke in alpha-tocopherol users vs non-users of alpha-tocopheral.<sup>11</sup> Similarly, U.S. male physicians from the Physicians’ Health Study II had increased incidence of hemorrhagic stroke in vitamin E group vs placebo.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Corrigan JJ and Marcus FI, “Coagulopathy Associated With Vitamin E Ingestion,” <i>JAMA</i>, 1974, 230:1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479598\">[PubMed 4479598]</a></p>\n<p>2. Schrogie JJ, “Coagulopathy and Fat-Soluble Vitamins,” <i>JAMA</i>, 1975, 232:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172961\">[PubMed 1172961]</a></p>\n<p>3. Kim JM and White RH, “Effect of Vitamin E on the Anticoagulant Response to Warfarin,” <i>Am J Cardiol</i>, 1996, 77:545-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=86296604\">[PubMed 86296604]</a></p>\n<p>4. Corrigan JJ and Ulfers LL, “Effect of Vitamin E on Prothrombin Levels in Warfarin-Induced Vitamin K Deficiency,” <i>Am J Clin Nutr</i>, 1981, 34:1701-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7282596\">[PubMed 7282596]</a></p>\n<p>5. Booth SL, Golly I, Sacheck JM, et al, “Effect of Vitamin E Supplementation on Vitamin K Status in Adults with Normal Coagulation Status,” <i>Am J Clin Nutr</i>, 2004, 80:143-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213041\">[PubMed 15213041]</a></p>\n<p>6. Ferro D, Basili S, Pratico D, et al, “Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients.” <i>Blood</i>, 1999, 93(9): 2945-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10216089\">[PubMed 10216089]</a></p>\n<p>7. Violi F, Pignatelli P, Basili S, “Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding,” <i>Circulation</i>, 2010, 121:1033-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20194876\">[PubMed 20194876]</a></p>\n<p>8. Lee IM, Cook NR, Gaziano JM, et al, “Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial,” <i>JAMA</i>, 2005, 294:56-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998891\">[PubMed 15998891]</a></p>\n<p>9. Cook NR, Albert CM, Gaziano JM, et al, “A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women: Results from the Women’s Antioxidant Cardiovascular Study,” <i>Arch Intern Med</i>, 2007, 167:1610-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17698683\">[PubMed 17698683]</a></p>\n<p>10. Yusuf S, Dagenais G, Pogue J, et al, “Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients: The Heart Outcomes Prevention Evaluation Study Investigators,” <i>N Engl J Med</i>, 2000, 342:154-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10639540\">[PubMed 10639540]</a></p>\n<p>11. Anonymous, “The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers: The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group,” <i>N Engl J Med</i>, 1994, 330:1029-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127329\">[PubMed 8127329]</a></p>\n<p>12. Sesso HD, Buring JE, Christen WG, et al, “Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II Randomized Controlled Trial,” <i>JAMA</i>, 2008, 300:2123-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18997197\">[PubMed 18997197]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9483":"<p><b>Title</b> Agents with Antiplatelet Properties / Vitamin E (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin E (Systemic) may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased platelet inhibition in patients receiving vitamin E with antiplatelet agents.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachidonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein Iib expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9484":"<p><b>Title</b> CycloSPORINE (Systemic) / Vitamin E (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin E (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum cyclosporine concentrations with vitamin E supplement initiation/dose increase.</p> \n<p><b>Discussion</b> In three clinical studies of cyclosporine maintained transplant recipients, antioxidant regimens containing 267-500 mg/day vitamin E were associated with 24-30% lower trough cyclosporine concentrations compared to baseline values or placebo treatment.<sup>1,2,3</sup> All regimens also contained ascorbic acid (500-1000 mg/day) and one contained beta carotene (6 mg/day). The mechanism of this interaction is unknown, and it is unclear whether the observed changes may be attributable to vitamin E or the other supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lake KD, Aaronson KD, Gorman LE, et al, “Effect of Oral Vitamin E and C Therapy on Calcineurin Inhibitor Levels in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(8):990-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16102431\">[PubMed 16102431]</a></p>\n<p>2. Blackhall ML, Fassett RG, Sharman JE, et al, “Effects of Antioxidant Supplementation on Blood Cyclosporine A and Glomerular Filtration Rate in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2005, 20(9):1970-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998657\">[PubMed 15998657]</a></p>\n<p>3. de Vries AP, Oterdoom LH, Gans RO, et al, “Supplementation With Anti-oxidants Vitamin C and E Decreases Cyclosporine A Trough-Levels in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2006, 21(1):231-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115840\">[PubMed 16115840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9485":"<p><b>Title</b> Ibrutinib / Vitamin E (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The ibrutinib Canadian product monograph recommends avoiding this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin E (Systemic) may enhance the antiplatelet effect of Ibrutinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for evidence of bleeding/bleeding risk (eg, easily bruising, blood in stools or urine, prolonged or uncontrolled bleeding) in patients receiving ibrutinib in combination with vitamin E supplements. The ibrutinib Canadian product monograph recommends avoiding this combination.</p> \n<p><b>Discussion</b> The ibrutinib Canadian product monograph states that its use in combination with certain supplements (flaxseed oil, omega-3 fatty acids, and vitamin E) should be avoided due to a theoretical potential for the supplements to increase bleeding risk via antiplatelet effects.<sup>1</sup> Ibrutinib US prescribing information, in contrast, recommends only a careful risk-benefit assessment for use with anticoagulant or antiplatelet agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Imbruvica</i> (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2014.</p>\n<p>2. <i>Imbruvica</i> (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9486":"<p><b>Title</b> Iron Salts / Vitamin E (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Vitamin E (Systemic) may diminish the therapeutic effect of Iron Salts. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Ferumoxytol, Iron Acetyltransferrin, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exception</b> Ferric Citrate</p>\n</div> \n<p><b>Discussion</b> The hematologic response to iron administration (iron dextran 5 mg/kg/day for 3 days, then oral ferrous sulfate beginning day 7) was decreased in anemic children when also administered oral vitamin E on iron days 1 through 3 (200 units).<sup>1</sup> The reticulocyte response in patients receiving vitamin E was 4.4% versus 14.4% in those not receiving vitamin E. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Melhorn DK and Gross S, “Relationships Between Iron-Dextran and Vitamin E in Iron Deficiency Anemia in Children,” <i>J Lab Clin Med</i>, 1969, 74:789-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5350205\">[PubMed 5350205]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9487":"<p><b>Title</b> Vitamin E (Systemic) / Tipranavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to tipranavir oral solution.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may enhance the adverse/toxic effect of Vitamin E (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients taking tipranavir oral solution are advised to avoid taking additional vitamin E, beyond the amounts contained in a multivitamin product. This interaction does not apply to tipranavir capsules.</p> \n<p><b>Discussion</b> Tipranavir prescribing information recommends that patients taking the tipranavir oral solution avoid using supplemental vitamin E, beyond the amounts contained in a multivitamin product, due to concerns about excessive vitamin E intake.<sup>1</sup> Tipranavir oral solution contains 116 IU/mL of vitamin E.<sup>1</sup> This interaction does not apply to tipranavir capsules.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9488":"<p><b>Title</b> Aminoglycosides / Mannitol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mannitol (Systemic) may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Systemic aminoglycosides should not be used together with potent diuretics such as mannitol.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for some aminoglycosides include a warning that potent diuretics should not be used with an aminoglycoside.<sup>1,2,3</sup> Some labeling specifically calls out certain diuretics, including mannitol.<sup>1,2</sup> Though published data detailing such an interaction are not available, a search of the FDA Adverse Event Reporting System (FAERS) covering reports between the first quarter of 2010 and the third quarter of 2012 revealed 54 cases of possible/likely renal toxicities that involved concurrent use of mannitol and gentamicin, tobramycin, or amikacin. While such a non-controlled review of reported cases is not definitive evidence of the presence or absence of such an interaction, it does provide some support for the inclusion of such a warning in aminoglycoside prescribing information.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tobi Podhaler</i> (tobramycin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p>2. Tobramycin [prescribing information]. Buffalo Grove, IL: Akorn-Strides, LLC; August 2007.</p>\n<p>3. Gentamicin [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; September 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9489":"<p><b>Title</b> Brexpiprazole / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Following discontinuation of the CYP3A4 inducer, decrease the brexpiprazole dose to the original or standard dose over a period of 1 to 2 weeks. Monitor patient response closely when brexpiprazole is used with a strong CYP3A4 inducer due to the potential for decreased brexpiprazole exposure and effects.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The brexpiprazole AUC was approximately 75% lower with concurrent use of the strong CYP3A4 inducer rifampin.<sup>1</sup> As a result, the brexpiprazole prescribing information recommends an increase in the brexpiprazole dose when used together with a strong CYP3A4 inducer. The likely mechanism for this reported interaction is induction of the CYP3A4-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9490":"<p><b>Title</b> Brexpiprazole / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Brexpiprazole dose reductions are recommended with concomitant use of both a CYP3A4 inhibitor and a moderate or strong CYP2D6 inhibitor.</p></li>\n <li><p><b>Phenotype</b> (Poor metabolizer): If brexpiprazole is used with a moderate CYP3A4 inhibitor in a patient who is a CYP2D6 poor metabolizer (i.e., deficient CYP2D6 activity), the brexpiprazole dose should be reduced to 25% of the usual dose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response closely when brexpiprazole is used with a moderate CYP3A4 inhibitor due to the potential for increased brexpiprazole exposure and effects. If brexpiprazole is to be used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose. Increase brexpiprazole doses proportionately following discontinuation of the CYP3A4 inhibitor. Brexpiprazole dose reductions are recommended with concurrent use of strong CYP2D6 inhibitors, so some brexpiprazole dose reduction may still be required if the moderate CYP3A4 is discontinued. Additionally, if brexpiprazole is used with a moderate CYP3A4 inhibitor in a patient who is a CYP2D6 poor metabolizer (i.e., possesses two loss-of-function alleles for <i>CYP2D6</i>, which is the gene that codes for the CYP2D6 enzyme, resulting in deficient CYP2D6 activity), the brexpiprazole dose should be reduced to 25% of the usual dose.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Specific data concerning the use of brexpiprazole with a moderate CYP3A4 inhibitor are not available, but the brexpiprazole AUC was approximately 2-fold higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> The brexpiprazole prescribing information does not recommend routine dose adjustment with moderate CYP3A4 inhibitors, but brexpiprazole dose adjustment is recommended for patients taking both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor. A similar dose reduction is recommended for patients taking a moderate CYP3A4 inhibitor who are CYP2D6 poor metabolizers (i.e., with genetic variations in the <i>CYP2D6</i> gene resulting in relatively inactive CYP2D6). This is likely based on observations of a 5.1-fold increase in brexpiprazole AUC with concurrent use of both a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.<sup>1</sup><br><br>The likely mechanism for this reported interaction is inhibition of the CYP3A4-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9491":"<p><b>Title</b> Brexpiprazole / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Further brexpiprazole dose reductions are recommended with concomitant use of both a CYP3A4 inhibitor and a moderate or strong CYP2D6 inhibitor.</p></li>\n <li><p><b>Phenotype</b>: If brexpiprazole is used with a strong CYP3A4 inhibitor in a patient who is a CYP2D6 poor metabolizer (i.e., deficient CYP2D6 activity), the brexpiprazole dose should be reduced to 25% of the usual dose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If brexpiprazole is to be used together with a strong CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 50% of the usual dose. If brexpiprazole is to be used together with both a strong CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose. Increase brexpiprazole doses proportionately following discontinuation of the CYP3A4 inhibitor. Brexpiprazole dose reductions are recommended with concurrent use of strong CYP2D6 inhibitors, so some brexpiprazole dose reduction may still be required if the strong CYP3A4 is discontinued. Additionally, if brexpiprazole is used with a strong CYP3A4 inhibitor in a patient who is a CYP2D6 poor metabolizer (i.e., possesses two loss-of-function alleles for <i>CYP2D6</i>, which is the gene that codes for the CYP2D6 enzyme, resulting in deficient CYP2D6 activity), the brexpiprazole dose should be reduced to 25% of the usual dose. Monitor patient response closely with any of these combinations due to the potential for increased brexpiprazole exposure and effects.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The brexpiprazole AUC was approximately 2-fold higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> As a result, the brexpiprazole prescribing information recommends that the brexpiprazole dose be reduced to 50% of the usual dose with concurrent use of a strong CYP3A4 inhibitors. A further brexpiprazole dose adjustment is recommended for patients taking both a strong CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor. A similar dose reduction is recommended for patients taking a strong CYP3A4 inhibitor who are CYP2D6 poor metabolizers (i.e., with genetic variations in the <i>CYP2D6</i> gene resulting in relatively inactive CYP2D6). This is likely based on observations of a 5.1-fold increase in brexpiprazole AUC with concurrent use of both a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.<sup>1</sup><br><br>The likely mechanism for this reported interaction is inhibition of the CYP3A4-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9492":"<p><b>Title</b> Brexpiprazole / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Further brexpiprazole dose reductions are recommended with concomitant use of both a CYP2D6 inhibitor and a moderate or strong CYP3A4 inhibitor.</p></li>\n <li><p><b>Indication</b>: If treating major depressive disorder, no routine brexpiprazole dose adjustment is required, but brexpiprazole dose reductions are recommended with this combination when using brexpiprazole for other indications.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If brexpiprazole is to be used together with a strong CYP2D6 inhibitor, the brexpiprazole dose should be reduced to 50% of the usual dose. Per brexpiprazole labeling, this dose reduction is not required if treating major depressive disorders. If brexpiprazole is to be used together with both a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose. Increase brexpiprazole doses proportionately following discontinuation of the CYP2D6 inhibitor. Brexpiprazole dose reductions are recommended with concurrent use of strong CYP3A4 inhibitors, so some brexpiprazole dose reduction may still be required if the strong CYP2D6 is discontinued. Monitor patient response closely with any of these combinations due to the potential for increased brexpiprazole exposure and effects.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The brexpiprazole AUC was approximately 2-fold higher with concurrent use of the strong CYP2D6 inhibitor quinidine.<sup>1</sup> As a result, the brexpiprazole prescribing information recommends reducing the brexpiprazole dose to 50% of the usual dose with strong CYP2D6 inhibitors. Further brexpiprazole dose adjustment is recommended for patients taking both a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor. This is likely based on observations of a 5.1-fold increase in brexpiprazole AUC with concurrent use of both a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.<sup>1</sup><br><br>The likely mechanism for this reported interaction is inhibition of the CYP2D6-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9493":"<p><b>Title</b> Brexpiprazole / CYP2D6 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Brexpiprazole dose reductions are recommended with concomitant use of a CYP2D6 inhibitor and moderate or strong CYP3A4 inhibitor.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response closely when brexpiprazole is used with a moderate CYP2D6 inhibitor due to the potential for increased brexpiprazole exposure and effects. If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose. Increase brexpiprazole doses proportionately following discontinuation of the CYP3A4 inhibitor. Brexpiprazole dose reductions are recommended with concurrent use of strong CYP3A4 inhibitors, so some brexpiprazole dose reduction may still be required if the moderate CYP2D6 is discontinued.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> Specific data concerning the use of brexpiprazole with a moderate CYP2D6 inhibitor are not available, but the brexpiprazole AUC was approximately 2-fold higher with concurrent use of the strong CYP2D6 inhibitor quinidine.<sup>1</sup> The brexpiprazole prescribing information does not recommend routine dose adjustment with moderate CYP2D6 inhibitors, but brexpiprazole dose adjustment is recommended for patients taking both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor. This is likely based on observations of a 5.1-fold increase in brexpiprazole AUC with concurrent use of both a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.<sup>1</sup><br><br>The likely mechanism for this reported interaction is inhibition of the CYP2D6-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9494":"<p><b>Title</b> Brexpiprazole / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Brexpiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If brexpiprazole is used together with St Johns wort, which is a CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Following discontinuation of St Johns wort, decrease the brexpiprazole dose to the original or standard dose over a period of 1 to 2 weeks. Monitor patient response closely when brexpiprazole is used with St Johns wort due to the potential for decreased brexpiprazole exposure and effects.</p> \n<p><b>Discussion</b> The brexpiprazole AUC was approximately 75% lower with concurrent use of the strong CYP3A4 inducer rifampin.<sup>1</sup> As a result, the brexpiprazole prescribing information recommends an increase in the brexpiprazole dose when used together with a strong CYP3A4 inducer or St Johns wort, which is a moderate but highly variable CYP3A4 inducer. The likely mechanism for this reported interaction is St Johns wort induction of the CYP3A4-mediated metabolism of brexpiprazole, which is metabolized by both CYP2D6 and CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9495":"<p><b>Title</b> Budesonide (Systemic) / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess. Patients should avoid grapefruit juice consumption.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Although specific studies with oral budesonide and moderate CYP3A4 inhibitors are not available, the prescribing information for oral budesonide states that concomitant oral administration with the strong CYP3A4 inhibitor ketoconazole resulted in an 8-fold increase in systemic budesonide exposure.<sup>1,2</sup> In a pharmacokinetic study of 8 healthy volunteers, ketoconazole (200 mg once daily x 4 days) increased the budesonide (3 mg single oral dose) AUC 6.5-fold when administered concomitantly.<sup>3</sup> When separated by 12 hours, ketoconazole increased the budesonide AUC 3.8-fold.<sup>3</sup> In a pharmacokinetic study described in the budesonide prescribing information, administration of grapefruit juice (200 mL three times daily x 4 days) increased the budesonide (3 mg single oral dose) AUC 2.3-fold.<sup>1,2,4</sup> Published case reports describe patients who presented with Cushing syndrome that was likely secondary to an interaction between oral budesonide and the strong CYP3A4 inhibitors atazanavir/ritonavir and voriconazole.<sup>5,6</sup><br><br>Prescribing information for oral budesonide recommends avoiding use with CYP3A4 inhibitors.<sup>1,2</sup> In cases where CYP3A4 inhibitors and budesonide are combined, close monitoring of patients for signs and symptoms of corticosteroid excess is recommended.<sup>2</sup> Avoiding concomitant use of grapefruit juice is also recommended.<sup>1,2</sup><br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 (intestinal and hepatic) metabolism of budesonide, which is a CYP3A substrate, by CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Entocort EC (budesonide) capsules [prescribing information]. Allegan, MI: Perrigo; April 2016.</p>\n<p>2. Uceris (budesonide) extended release tablets [prescribing information]. San Diego, CA: Santarus Inc; January 2013.</p>\n<p>3. Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. <i>Clin Pharmacol Ther</i>. 2000;68(1):13-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10945311\">[PubMed 10945311]</a> </p>\n<p>4. Seidegard J, Randvall G, Nyberg L, Borga O. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. <i>Pharmazie</i>. 2009;64(7):461-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19694184\">[PubMed 19694184]</a></p>\n<p>5. Frankel JK, Packer CD. Cushing's syndrome due to antiretroviral-budesonide interaction. <i>Ann Pharmacother</i>. 2011;45(6):823-824. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21558486\">[PubMed 21558486]</a></p>\n<p>6. Jones W, Chastain CA, Wright PW. Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide. <i>Pharmacotherapy</i>. 2014;34(7):e116-e119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24757038\">[PubMed 24757038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9496":"<p><b>Title</b> Budesonide (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and a strong CYP3A4 inhibitor, they should be closely monitored for signs and symptoms of corticosteroid excess.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Prescribing information for oral budesonide states that concomitant oral administration with the strong CYP3A4 inhibitor ketoconazole resulted in an 8-fold increase in systemic budesonide exposure.<sup>1,2</sup> In a pharmacokinetic study of 8 healthy volunteers, ketoconazole (200 mg once daily x 4 days) increased the budesonide (3 mg single oral dose) AUC 6.5-fold when administered concomitantly.<sup>3</sup> When separated by 12 hours, ketoconazole increased the budesonide AUC 3.8-fold.<sup>3</sup> When budesonide was locally instilled into different segments of the intestines with or without prior instillation of ketoconazole, the budesonide bioavailability approximately doubled with ketoconazole.<sup>4</sup> In support of these studies, published case reports describe patients who presented with Cushing syndrome that was likely secondary to an interaction between oral budesonide and the strong CYP3A4 inhibitors atazanavir/ritonavir and voriconazole.<sup>5,6</sup><br><br>Prescribing information for oral budesonide recommends avoiding use with CYP3A4 inhibitors.<sup>1,2</sup> In cases where CYP3A4 inhibitors and budesonide are combined, close monitoring of patients for signs and symptoms of corticosteroid excess is recommended.<sup>2</sup><br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 (intestinal and hepatic) metabolism of budesonide, which is a CYP3A substrate, by CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Entocort EC (budesonide) capsules [prescribing information]. Allegan, MI: Perrigo; April 2016.</p>\n<p>2. Uceris (budesonide) extended release tablets [prescribing information]. San Diego, CA: Santarus Inc; January 2013.</p>\n<p>3. Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. <i>Clin Pharmacol Ther</i>. 2000;68(1):13-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10945311\">[PubMed 10945311]</a> </p>\n<p>4. Seidegard J, Nyberg L, Borga O. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. <i>Eur J Pharm Sci</i>. 2008;35(4):264-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18706998\">[PubMed 18706998]</a></p>\n<p>5. Frankel JK, Packer CD. Cushing's syndrome due to antiretroviral-budesonide interaction. <i>Ann Pharmacother</i>. 2011;45(6):823-824. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21558486\">[PubMed 21558486]</a></p>\n<p>6. Jones W, Chastain CA, Wright PW. Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide. <i>Pharmacotherapy</i>. 2014;34(7):e116-e119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24757038\">[PubMed 24757038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9497":"<p><b>Title</b> Budesonide (Systemic) / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Budesonide (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should avoid ingestion of grapefruit juice while taking oral budesonide.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the budesonide prescribing information, administration of grapefruit juice (200 mL three times daily x 4 days) increased the budesonide (3 mg single oral dose) AUC 2.3-fold in 8 healthy volunteers.<sup>1,2,4</sup> As a result, the prescribing information for oral budesonide recommends that patients avoid grapefruit juice while being treated with oral budesonide.<sup>1,2</sup><br><br>The likely mechanism of this interaction is inhibition of intestinal CYP3A4 by grapefruit juice, an enzyme responsible for budesonide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Entocort EC (budesonide) capsules [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; December 2011.</p>\n<p>2. Uceris (budesonide) extended release tablets [prescribing information]. San Diego, CA: Santarus Inc; January 2013.</p>\n<p>3. Seidegard J, Randvall G, Nyberg L, Borga O. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. <i>Pharmazie</i>. 2009;64(7):461-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19694184\">[PubMed 19694184]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9498":"<p><b>Title</b> Budesonide (Oral Inhalation) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for signs and symptoms of corticosteroid excees if inhaled budesonide is used in a patient taking a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, itraconazole (200 mg once daily x 5 days) increased the budesonide (1,000 mcg inhaled) maximum serum concentration and AUC 1.6- and 4.2-fold, respectively.<sup>1</sup> Additionally, endogenous cortisol production was significantly decreased by itraconazole.<sup>1</sup> In support of this study, numerous case reports have been published that describe patients who experienced symptoms of corticosteroid excess with the concomitant use of inhaled budesonide and a strong CYP3A4 inhibitor.<sup>2,3,4,5,6,7,8,9</sup> <br><br>Prescribing information for inhaled budesonide products warns that use of strong CYP3A4 inhibitors during treatment with inhaled budesonide may result in increased systemic exposure and an increased risk of corticosteroid related adverse events.<sup>10,11</sup><br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 metabolism of budesonide, which is a CYP3A substrate, by CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. <i>Clin Pharmacol Ther</i>. 2002;72(4):362-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386638\">[PubMed 12386638]</a></p>\n<p>2. De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. <i>Eur J Pediatr</i>. 2003;162(7-8):488-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12719971\">[PubMed 12719971]</a></p>\n<p>3. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. <i>Ann Pharmacother</i>. 2004;38(1):46-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742792\">[PubMed 14742792]</a></p>\n<p>4. De Watcher E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. <i>J Cyst Fibros</i>. 2003;2(2):72-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15463853\">[PubMed 15463853]</a></p>\n<p>5. Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide. <i>S Afr Med J</i>. 2010;100(5):296-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20460021\">[PubMed 20460021]</a></p>\n<p>6. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. <i>J Asthma</i>. 2010;47(7):830-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653496\">[PubMed 20653496]</a></p>\n<p>7. Yoganathan K, David L, Williams C, Jones K. Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. <i>Int J STD AIDS</i>. 2012;23(7):520-521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22844010\">[PubMed 22844010]</a></p>\n<p>8. Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. <i>Endocr Pract</i>. 2013;19(6):e138-e141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23807527\">[PubMed 23807527]</a></p>\n<p>9. Main KM, Skov M, Sillesen IB, et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient. <i>Acta Paediatr</i>. 2002;91(9):1008-1011. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12412882\">[PubMed 12412882]</a></p>\n<p>10. Symbicort (budesonide/formoterol) [prescribing information]. Wilmington, DE: AstraZeneca LP; June 2010.</p>\n<p>11. Pulmicort Flexhaler (budesonide) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9499":"<p><b>Title</b> Budesonide (Oral Inhalation) / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Budesonide (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with inhaled budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits. With any use of this combination, monitor patients closely for signs and symptoms of corticosteroid excess/toxicity.</p> \n<p><b>Discussion</b> Although specific data regarding this drug combination are not available, evidence for this interaction is supported by data describing the combination of inhaled budesonide and other strong CYP3A4 inhibitors. In a pharmacokinetic study of 10 healthy volunteers, itraconazole (200 mg once daily x 5 days) increased the budesonide (1,000 mcg inhaled) maximum serum concentration and AUC 1.6- and 4.2-fold, respectively.<sup>1</sup> Additionally, endogenous cortisol production was significantly decreased by itraconazole.<sup>1</sup> In support of this study, numerous case reports have been published that describe patients who experienced symptoms of corticosteroid excess with the concomitant use of inhaled budesonide and a strong CYP3A4 inhibitor.<sup>2,3,4,5,6,7,8,9</sup> <br><br>The telaprevir prescribing information recommends avoiding use in combination with inhaled budesonide unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.<sup>10</sup><br><br>The specific mechanism for this potential interaction is inhibition of the CYP3A-mediated metabolism of budesonide by telaprevir.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. <i>Clin Pharmacol Ther</i>. 2002;72(4):362-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386638\">[PubMed 12386638]</a></p>\n<p>2. De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. <i>Eur J Pediatr</i>. 2003;162(7-8):488-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12719971\">[PubMed 12719971]</a></p>\n<p>3. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. <i>Ann Pharmacother</i>. 2004;38(1):46-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742792\">[PubMed 14742792]</a></p>\n<p>4. De Watcher E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. <i>J Cyst Fibros</i>. 2003;2(2):72-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15463853\">[PubMed 15463853]</a></p>\n<p>5. Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide. <i>S Afr Med J</i>. 2010;100(5):296-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20460021\">[PubMed 20460021]</a></p>\n<p>6. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. <i>J Asthma</i>. 2010;47(7):830-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653496\">[PubMed 20653496]</a></p>\n<p>7. Yoganathan K, David L, Williams C, Jones K. Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. <i>Int J STD AIDS</i>. 2012;23(7):520-521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22844010\">[PubMed 22844010]</a></p>\n<p>8. Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. <i>Endocr Pract</i>. 2013;19(6 ):e138-e141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23807527\">[PubMed 23807527]</a></p>\n<p>9. Main KM, Skov M, Sillesen IB, et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient. <i>Acta Paediatr</i>. 2002;91(9):1008-1011. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12412882\">[PubMed 12412882]</a></p>\n<p>10. Incivek (telaprevir) [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}